US5155027A - Method of producing secreted receptor analogs and biologically active peptide dimers - Google Patents

Method of producing secreted receptor analogs and biologically active peptide dimers Download PDF

Info

Publication number
US5155027A
US5155027A US07/347,291 US34729189A US5155027A US 5155027 A US5155027 A US 5155027A US 34729189 A US34729189 A US 34729189A US 5155027 A US5155027 A US 5155027A
Authority
US
United States
Prior art keywords
pdgf
fragment
receptor
plasmid
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/347,291
Other languages
English (en)
Inventor
Andrzej Z. Sledziewski
Lillian A. Bell
Wayne R. Kindsvogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Assigned to ZYMOGENETICS, INC., A CORP. OF WA reassignment ZYMOGENETICS, INC., A CORP. OF WA ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BELL, LILLIAN A., KINDSVOGEL, WAYNE R., SLEDZIEWSKI, ANDRZEJ Z.
Publication of US5155027A publication Critical patent/US5155027A/en
Application granted granted Critical
Priority to US08/180,195 priority Critical patent/US5567584A/en
Priority to US08/475,458 priority patent/US5843725A/en
Priority to US08/477,329 priority patent/US5750375A/en
Priority to US08/980,400 priority patent/US6018026A/en
Priority to US09/435,059 priority patent/US6323323B1/en
Priority to US09/583,459 priority patent/US6291212B1/en
Priority to US09/583,210 priority patent/US6291646B1/en
Priority to US09/583,449 priority patent/US6300099B1/en
Priority to US09/955,363 priority patent/US20020173621A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Definitions

  • the present invention is generally directed toward the expression of proteins, and more specifically, toward the expression of growth factor receptor analogs and biologically active peptide dimers.
  • receptors and ligands e.g., hormones
  • ligands e.g., hormones
  • Ligands fall into two classes: those that have stimulatory activity, termed agonists; and those that block the effects elicited by the original ligands, termed antagonists.
  • agonists that differ in structure and composition from the original ligand may be medically useful.
  • agonists that are smaller than the original ligand may be especially useful.
  • the bioavailability of these smaller agonists may be greater than that of the original ligand. This may be of particular importance for topical applications and for instances when diffusion of the agonist to its target sites is inhibited by poor circulation.
  • Agonists may also have slightly different spectra of biological activity and/or different potencies, allowing them to be used in very specific situations.
  • Antagonists that are smaller and chemically simpler than the native ligand may be produced in greater quantity and at lower cost.
  • the identification of antagonists which specifically block, for example, growth factor receptors has important pharmaceutical applications.
  • Antagonists that block receptors against the action of endogenous, native ligand may be used as therapeutic agents for conditions including atherosclerosis, autocrine tumors, fibroplasia and keloid formation.
  • the discovery of new ligands that may be used in pharmaceutical applications has centered around designing compounds by chemical modification, complete synthesis, and screening potential ligands by complex and costly screening procedures.
  • the process of designing a new ligand usually begins with the alteration of the structure of the original effector molecule. If the original effector molecule is known to be chemically simple, for example, a catecholamine or prostaglandin, the task is relatively straightforward. However, if the ligand is structurally complex, for example, a peptide hormone or a growth factor, finding a molecule which is functionally equivalent to the original ligand becomes extremely difficult.
  • potential ligands are screened using radioligand binding methods (Lefkowitz et al., Biochem. Biophys. Res. Comm. 60: 703-709, 1974; Aurbach et al., Science 186: 1223-1225, 1974; Atlas et al. Proc. Natl. Acad. Sci. USA 71: 4246-4248, (1974).
  • Potential ligands can be directly assayed by binding the radiolabeled compounds to responsive cells, to the membrane fractions of disrupted cells, or to solubilized receptors.
  • potential ligands may be screened by their ability to compete with a known labeled ligand for cell surface receptors.
  • ligand binding assays require the isolation of responsive cell lines. Often, only a limited subset of cells is responsive to a particular agent, and such cells may be responsive only under certain conditions. In addition, these cells may be difficult to grow in culture or may possess a low number of receptors.
  • PDGF platelet-derived growth factor
  • interleukin-2 receptor IL-2-R
  • Rubin et al. J. Immun. 135: 3172-3177, 1985
  • Bailon et al. Bio/Technology 1195-1198, 1987
  • IL-2-R matrix-bound interleukin-2 receptor
  • the insulin receptor (Ellis et al., J. Cell Biol. 150: 14a, 1987), the HIV-1 envelope glycoprotein cellular receptor CD4 (Smith et al., Science 238: 1704-1707, 1987) and the epidermal growth factor (EGF) receptor (Livneh et al., J. Biol. Chem. 261: 12490-12497, 1986) have been secreted from mammalian cells using truncated cDNAs that encode portions of the extracellular domains.
  • EGF epidermal growth factor
  • Secreted ligand-binding receptors may be used in a variety of assays, which include assays to determine the presence of ligand in biological fluids and assays to screen for potential agonists and antagonists.
  • Current methods for ligand screening and ligand/receptor binding assays have been limited to those using preparations of whole cells or cell membranes for as a source for receptor molecules. The low reproducibility and high cost of producing such preparations does not lend itself to commercial production. There is therefore a need in the art for a method of producing secreted receptors.
  • the present invention discloses methods for producing secreted receptor analogs which including ligand-binding receptor analogs and secreted platelet-derived growth factor receptor (PDGF-R) analogs.
  • the present invention discloses methods for producing secreted peptide dimers.
  • a method for producing a secreted PDGF-R analog comprising (a) introducing into a eukaryotic host cell a DNA construct capable of directing the expression and secretion of a PDGF receptor analog, the DNA construct comprising a transcriptional promoter operatively linked to at least one secretory signal sequence followed downstream in proper reading frame by a DNA sequence encoding at least a portion of the extracellular domain of a PDGF-R, the portion including a ligand-binding domain; (b) growing the host cell in an appropriate growth medium; and (c) isolating the PDGF-R analogs from the host cell.
  • the dimerizing protein is yeast invertase. Within another embodiment, the dimerizing protein is at least a portion of an immunoglobulin light chain. Within another embodiment, the dimerizing protein is at least a portion of an immunoglobulin heavy chain.
  • a PDGF-R analog comprising the amino acid sequence of FIG. 1 from isoleucine, number 29 to methionine, number 441 is secreted.
  • a PDGF-R analog comprising the amino acid sequence of FIG. 1 from isoleucine, number 29 to lysine, number 531 is secreted.
  • Yet another aspect of the present invention discloses a method for producing a secreted, biologically active peptide dimer.
  • the method generally comprises a) introducing into a eukaryotic host cell a DNA construct capable of directing the expression and secretion of a peptide requiring dimerization for biological activity, the DNA construct comprising a transcriptional promoter operatively linked to at least one secretory signal sequence followed downstream by and in proper reading frame with a DNA sequence encoding a peptide requiring dimerization for biological activity joined to a dimerizing protein; (b) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the peptide; and (c) isolating the biologically active peptide dimer from the host cell.
  • a method for producing a secreted, biologically active peptide dimer comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream by and in proper reading frame with a first DNA sequence encoding a peptide requiring dimerization for biological activity joined to an immunoglobulin light chain constant region; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding at least one immunoglobulin heavy chain constant region domain selected from the group consisting of C H 1, C H 2, C H 3, and C H 4; (c) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the biologically active peptide dimer; and (d) isolating the biologically active peptide dimer from the host
  • the second DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • the second DNA sequence further encodes an immunoglobulin variable region joined upstream of and in proper reading frame with at least one immunoglobulin heavy chain constant region.
  • a method for producing a secreted, biologically active peptide dimer comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream by and in proper reading frame with a first DNA sequence encoding a peptide requiring dimerization for biological activity joined to at least one immunoglobulin heavy chain constant region domain selected from the group consisting of C H 1, C H 2, C H 3, and C H 4; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding an immunoglobulin light chain constant region; (c) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the biologically active peptide dimer; and (d) isolating the biologically active peptide dimer from the host
  • the first DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • the second DNA sequence further encodes an immunoglobulin variable region joined upstream of and in proper reading frame with an immunoglobulin light chain constant region.
  • a method for producing a secreted, biologically active peptide dimer comprising (a) introducing into a eukaryotic host cell a DNA construct comprising a transcriptional promoter operatively linked to a secretory signal sequence followed downstream by and in proper reading frame with a DNA sequence encoding a peptide requiring dimerization for biological activity joined to at least one immunoglobulin heavy chain constant region domain selected from the group consisting of C H 1, C H 2, C H 3, and C H 4; (b) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the biologically active peptide dimer; and (c) isolating the biologically active peptide dimer from the host cell.
  • the DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • a method for producing a secreted, biologically active peptide dimer comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream in by and in proper reading frame with a first DNA sequence encoding a first polypeptide chain of a peptide dimer joined to at least one immunoglobulin heavy chain constant region domain, selected from the group consisting of C H 1, C H 2, C H 3, and C H 4; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding a second polypeptide chain of a peptide dimer joined to an immunoglobulin light chain constant region domain; (c) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the biologically active peptide dimer
  • the first DNA sequence further encodes an immunoglobulin heavy chain hinge region domain wherein the hinge region is joined to at least one immunoglobulin heavy chain constant region domain.
  • the second DNA sequence further encodes an immunoglobulin variable region joined upstream of and in proper reading frame with an immunoglobulin light chain constant region.
  • a method for producing a secreted, ligand-binding receptor analog comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream by and in proper reading frame with a first DNA sequence encoding a polypeptide chain of a ligand-binding receptor analog joined to at least an immunoglobulin light chain constant region; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding at least one immunoglobulin heavy chain constant region domain, selected from the group consisting of C H 1, C H 2, C H 3, and C H 4; (c) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the ligand-binding receptor analog; and (d) isolating the ligand
  • the second DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • the second DNA sequence further encodes an immunoglobulin variable region joined upstream of and in proper reading frame with at least one immunoglobulin heavy chain constant region.
  • a method for producing a secreted, ligand-binding receptor analog comprising (a) introducing into a eukaryotic host cell a DNA construct comprising a transcriptional promoter operatively linked to a secretory signal sequence followed downstream by and in proper reading frame with a DNA sequence encoding a polypeptide chain of a ligand-binding receptor analog joined to at least one immunoglobulin heavy chain constant region domain, selected from the group C H 1, C H 2, C H 3, and C H 4; (b) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the ligand-binding receptor analog; and (c) isolating the ligand-binding receptor analog from the host cell.
  • the DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • a method for producing a secreted, ligand-binding receptor analog comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream in proper reading frame by a first DNA sequence encoding a polypeptide chain of a ligand-binding receptor analog joined to at least one immunoglobulin heavy chain constant region domain, selected from the group C H 1, C H 2, C H 3, and C H 4; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding at least an immunoglobulin light chain constant region; (c) growing the host cell in an appropriate growth medium under physiological conditions to allow the dimerization and secretion of the ligand-binding receptor analog; and (d) isolating the ligand-binding receptor analog from
  • the first DNA sequence further encodes an immunoglobulin heavy chain hinge region wherein the hinge region is joined to at least one heavy chain constant region domain.
  • the second DNA sequence further encodes an immunoglobulin variable region joined upstream of and in proper reading frame with an immunoglobulin light chain constant region.
  • a method for producing a secreted, ligand-binding receptor analog comprising (a) introducing into a eukaryotic host cell a first DNA construct comprising a transcriptional promoter operatively linked to a first secretory signal sequence followed downstream in proper reading frame by a first DNA sequence encoding a first polypeptide chain of a ligand-binding receptor analog joined to at least one immunoglobulin heavy chain constant region domain, selected from the group C H 1, C H 2, C H 3, and C H 4; (b) introducing into the host cell a second DNA construct comprising a transcriptional promoter operatively linked to a second secretory signal sequence followed downstream by and in proper reading frame with a second DNA sequence encoding a second polypeptide chain of a ligand binding receptor analog joined to an immunoglobulin light chain constant region domain.
  • the first DNA sequence further encodes an immunoglobulin heavy chain hinge region domain wherein the hinge region is joined to at least one immunoglobulin heavy
  • Host cells for use in the present invention include cultured mammalian cells and fungal cells.
  • strains of the yeast Saccharomyces cerevisiae are used as host cells.
  • cultured rodent myeloma cells are used as host cells.
  • a PDGF-R analog comprises the amino acid sequence of FIG. 1 from isoleucine, number 29 to methionine, number 441.
  • a PDGF-R analog comprises the amino acid sequence of FIG. 1 from isoleucine, number 29 to lysine, number 531.
  • PDGF-R analogs produced by the above-disclosed methods may be used, for instance, within a method for determining the presence of human PDGF or an isoform thereof in a biological sample.
  • a method for determining the presence of human PDGF or an isoform thereof in a biological sample comprises (a) incubating a polypeptide comprising a human PDGF receptor analog fused to a dimerizing protein with a biological sample suspected of containing human PDGF or an isoform thereof under conditions that allow the formation of receptor/ligand complexes; and (b) detecting the presence of receptor/ligand complexes, and therefrom determining the presence of human PDGF or an isoform thereof.
  • Suitable biological samples in this regard include blood, urine, plasma, serum, platelet and other cell lysates, platelet releasates, cell suspensions, cell-conditioned culture media, and chemically or physically separated portions thereof.
  • FIGS. 1 to 1C illustrate the nucleotide sequence of the PDGF receptor cDNA and the derived amino acid sequence of the primary translation product. Numbers above the lines refer to the nucleotide sequence; numbers below the lines refer to the amino acid sequence.
  • FIG. 2 illustrates the construction of pBTL10, pBTL11 and pBTL12.
  • FIG. 3 illustrates the construction of pCBS22.
  • FIG. 4 illustrates the construction of pBTL13 and pBTL14.
  • FIG. 5 illustrates the construction of pBTL15.
  • FIG. 6 illustrates the construction of pBTL22 and pBTL26.
  • FIG. 7 illustrates the construction of pSDL114. Symbols used are S.S., signal sequence, C k , immunoglobulin light chain constant region sequence; ⁇ prom, ⁇ promoter, ⁇ enh; ⁇ enhancer.
  • FIG. 8 illustrates the construction of pSDLB113. Symbols used are S.S., signal sequence; C H 1, C H 2, C H 3, immunoglobulin heavy chain constant region domain sequences; H, immunoglobulin heavy chain hinge region sequence; M, immunoglobulin membrane anchor sequences; C.sub. ⁇ 1M, immunoglobulin heavy chain constant region and membrane anchor sequences.
  • FIG. 9 illustrates the constructions pBTL115, pBTL114, p ⁇ 5V H HuC.sub. ⁇ 1M-neo, plC ⁇ 5V.sub. ⁇ HuC.sub. ⁇ -neo.
  • Symbols used are set forth in FIGS. 7 and 8, and also include L H , mouse immunoglobulin heavy chain signal sequence; V H , mouse immunoglobulin heavy chain variable region sequence; E, mouse immunoglobulin heavy chain enhancer sequence; L.sub. ⁇ , mouse immunoglobulin light chain signal sequence; ⁇ 5V.sub. ⁇ , mouse immunoglobulin light chain variable region sequence; Neo R , E. coli neomycin resistance gene.
  • FIG. 10 illustrates the constructions Zem229R, p ⁇ 5V H Fab-neo and pWKI. Symbols used are set forth in FIG. 10.
  • DNA Construct A DNA molecule, or a clone of such a molecule, either single- or double-stranded that has been modified through human intervention to contain segments of DNA combined and juxtaposed in a manner that as a whole would not otherwise exist in nature.
  • Secretory Signal Sequence A DNA sequence encoding a secretory peptide.
  • a secretory peptide is an amino acid sequence that acts to direct the secretion of a mature polypeptide or protein from a cell.
  • Secretory peptides are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly sythesized proteins. Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the signal peptides from the mature proteins as it passes through the secretory pathway.
  • Processing sites may be encoded within the signal peptide or may be added to the signal peptide by, for example, vitro mutagenesis.
  • Certain secretory peptides may be used in concert to direct the secretion of polypeptides and proteins.
  • One such secretory peptide that may be used in combination with other secretory peptides is the third domain of the yeast Barrier protein.
  • Receptor Analog A portion of a receptor capable of binding ligand, anti-receptor antibodies, analogs or antagonists.
  • the amino acid sequence of the receptor analog may contain additions, substitutions or deletions as compared to the native receptor sequence.
  • a receptor analog may be, for example, the ligand-binding domain of a receptor joined to another protein.
  • Platelet-derived growth factor receptor (PDGF-R) analogs may, for example, comprise a portion of a PDGF receptor capable of binding anti-PDGF receptor antibodies, PDGF, PDGF isoforms, PDGF analogs, or PDGF antagonists.
  • Dimerizing Protein A polypeptide chain having affinity for a second polypeptide chain, such that the two chains associate under physiological conditions to form a dimer.
  • the second polypeptide chain may be the same or a different chain.
  • Biological activity A function or set of activities performed by a molecule in a biological context (i.e., in an organism or an in vitro facsimile thereof). Biological activities may include the induction of extracellular matrix secretion from responsive cell lines, the induction of hormone secretion, the induction of chemotaxis, the induction of mitogenesis, the induction of differentiation, or the inhibition of cell division of responsive cells.
  • a recombinant protein or peptide is considered to be biologically active if it exhibits one or more biological activities of its native counterpart.
  • Ligand A molecule, other than an antibody or an immunoglobulin, capable of being bound by the ligand-binding domain of a receptor.
  • the molecule may be chemically synthesized or may occur in nature.
  • Two or more DNA coding sequences are said to be joined when, as a result of in-frame fusions between the DNA coding sequences or as a result of the removal of intervening sequences by normal cellular processing, the DNA coding sequences are translated into a polypeptide fusion.
  • the present invention provides methods for producing biologically active peptide dimers and secreted receptor analogs, which include ligand-binding receptor analogs and PDGF receptor analogs.
  • Secreted receptor analogs may be used to screen for new compounds that act as agonists or antagonists when interacting with cells containing membrane-bound receptors.
  • the methods of the present invention provide peptides of therapeutic value that are biologically active only as dimers.
  • the present invention provides methods of producing peptide dimers that are biologically active only as non-covalently associated dimers.
  • Secreted, biologically active dimers that may be produced using the present invention include nerve growth factor, colony stimulating factor-1, factor XIII, and transforming growth factor ⁇ .
  • Ligand-binding receptor analogs that may be used in the present invention include the ligand-binding domains of the epidermal growth factor receptor (EGF-R) and the insulin receptor.
  • a ligand-binding domain is that portion of the receptor that is involved in binding ligand and is generally a portion or essentially all of the extracellular domain that extends from the plasma membrane into the extracellular space.
  • the ligand-binding domain of the EGF-R for example, resides in the extracellular domain.
  • EGF-R dimers have been found to exhibit higher ligand-binding affinity than EGF-R monomers (Boni-Schnetzler and Pilch, Proc. Natl. Acad. Sci. USA 84:7832-7836, 1987).
  • the insulin receptor (Ullrich et al., Nature 313:756-761, 1985) requires dimerization for biological activity.
  • PDGF-R platelet-derived growth factor receptor
  • PDGF-R platelet-derived growth factor receptor
  • BB platelet-derived growth factor receptor
  • the ⁇ -receptor which recognizes all three PDGF isoforms (PDGF-AA, PDGF-AB and PDGF-BB), has been described by Matsui et al. (Science 243:800-804, 1989). The primary translation products of these receptors indicated that each includes an extracellular domain implicated in the ligand-binding process, a transmembrane domain, and a cytoplasmic domain containing a tyrosine kinase activity. Matsui et al.
  • the present invention provides a standardized assay system, not previously available in the art, for determining the presence of PDGF, PDGF isoforms, PDGF agonists or PDGF antagonists using a secreted PDGF receptor analogs.
  • Such an assay system will typically involve combining the secreted PDGF receptor analog with a biological sample under physiological conditions which permit the formation of receptor-ligand complexes, followed by detecting the presence of the receptor-ligand complexes. Detection may be achieved through the use of a label attached to the PDGF receptor analog or through the use of a labeled antibody which is reactive with the receptor analog or the ligand.
  • a wide variety of labels may be utilized, such as radionuclides, fluorophores, enzymes and luminescers. Receptor-ligand complexes may also be detected visually, i.e., in immunoprecipitation assays which do not require the use of a label.
  • This assay system provides secreted PDGF receptor analogs that may be utilized in a variety of screening assays for, for example, screening for analogs of PDGF.
  • the present invention also provides a methods for measuring the level of PDGF and PDGF isoforms in biological fluids.
  • the present invention provides methods for producing peptide dimers that require dimerization for biological activity or enhancement of biological activity.
  • Peptides requiring dimerization of biological activity include, in addition to certain receptors nerve growth factor, colony-stimulating factor-1 (CSF-1), transforming growth factor ⁇ (TGF- ⁇ ), PDGF, and factor XIII.
  • Nerve growth factor is a non-covalently linked dimer (Harper et al., J. Biol. Chem. 257: 8541-8548, 1982).
  • CSF-1 which specifically stimulates the proliferation and differentiation of cells of mononuclear phagocytic lineage, is a disulfide-bonded homodimer (Retternmier et al., Mol. Cell. Biol.
  • TGF- ⁇ is biologically active as a disulfide-bonded dimer (Assoian et al., J. Biol. Chem. 258:7155-7160, 1983).
  • Factor XIII is a plasma protein that exists as a two chain homodimer in its activated form (Ichinose et al., Biochem. 25: 6900-6906, 1986).
  • PDGF as noted above, is a disulfide-bonded, two chain molecule (Murray et al., U.S. Pat. No. 4,766,073).
  • the present invention provides methods by which receptor analogs, including ligand-binding receptor analogs and PDGF-R analogs, requiring dimerization for activity may be secreted from host cells.
  • the methods described herein are particularly advantageous in that they allow the production of large quantities of purified receptors.
  • the receptors may be used in assays for the screening of potential ligands, in assays for binding studies, as imaging agents, and as agonists and antagonists within therapeutic agents.
  • a DNA sequence encoding a human PDGF receptor may be isolated as a cDNA using techniques known in the art (see, for example, Okayama and Berg, Mol. Cell. Biol. 161-170, 1982; Mol. Cell. Biol. 3: 280-289, 1983).
  • Sources of mRNA for use in the preparation of a cDNA library include the MG-63 human osteosarcoma cell line (available from ATCC under accession number CRL 1427), diploid human dermal fibroblasts and human embryo fibroblast and brain cells (Matsui et al., ibid.).
  • a cDNA encoding a ⁇ -PDGF-R has been cloned from a diploid human dermal fibroblast cDNA library using oligonucleotide probes complementary to sequences of the mouse PDGF receptor (Gronwald et al., ibid.).
  • An ⁇ -PDGF-R cDNA has been isolated by Matsui et al.
  • a cDNA encoding an ⁇ -PDGF-R may be isolated from a library prepared from MG-63 human osteosarcoma cells using a cDNA probe containing sequences encoding a cytoplasmic domain of the ⁇ -PDGF-R. Partial cDNA clones (fragments) can be extended by re-screening of the library with the cloned cDNA fragment until the full sequence is obtained.
  • a DNA sequence encoding a PDGF receptor analog consisting essentially of the extracellular domain of a PDGF receptor is used, although smaller DNA sequences encoding portions of at least 40% amino acids of the extracellular domain may be used.
  • EGF-R EGF-R
  • insulin receptor Ullrich et al., Nature 756-761, 1985
  • nerve growth factor Ullrich et al. Nature 303: 821-825, 1983
  • colony stimulating factor-1 Rettenmier et al., ibid.
  • transforming growth factor ⁇ Derynck et al., Nature 316: 701-705, 1985
  • PDGF Mitomycin et al., ibid.
  • factor XIII Ichinose et al., ibid.
  • secretory signal sequence is used in conjunction with the DNA sequence of interest.
  • Preferred secretory signals include the alpha factor signal sequence (pre-pro sequence) (Kurjan and Herkowitz, Cell 30: 933-943, 1982; Kurjan et al., U.S. Pat. No. 4,546,082; Brake, EP 116,201, 1983), the PHO5 signal sequence (Beck et al., WO 86/00637), the BARI secretory signal sequence (MacKay et al., U.S. Pat. No.
  • immunoglobulin V H signal sequences (Loh et al., Cell: 85-93, 1983; Watson Nuc. Acids. Res. 12: 5145-5164, 1984) and immunoglobulin V.sub. ⁇ signal sequences (Watson, ibid.).
  • Particularly preferred signal sequences are the SUC2 signal sequence (Carlson et al., Mol. Cell. Biol. 439-447, 1983) and PDGF receptor signal sequences.
  • secretory signal sequences may be synthesized according to the rules established, for example, by von Heinje (Eur. J. Biochem. 133: 17-21, 1983; J. Mol. Biol. 99-105 1985; Nuc. Acids. Res. 14: 4683-3690, 1986).
  • Secretory signal sequences may be used singly or may be combined.
  • a first secretory signal sequence may be used singly or combined with a sequence encoding the third domain of Barrier (described in co-pending commonly assigned U.S. patent application Ser. No. 104,316, now abandoned, which is incorporated by reference herein in its entirety).
  • the third domain of Barrier may be positioned in proper reading frame 3' of the DNA sequence of interest or 5' to the DNA sequence and in proper reading frame with both the secretory signal sequence and the DNA sequence of interest.
  • a sequence encoding a dimerizing protein is joined to a sequence encoding a peptide dimer or a receptor analog, and this fused sequence is joined in proper reading frame to a secretory signal sequence.
  • the present invention utilizes such an arrangement to drive the association of the peptide or receptor analog to form a biologically active molecule upon secretion.
  • Suitable dimerizing proteins include the S. cerevisiae repressible acid phosphatase (Mizunaga et al., J. Biochem. (Tokyo) 103: 321-326, 1988), the S. cerevisiae type 1 killer preprotoxin (Sturley et al., EMBO J.
  • S. cerevisiae invertase is used to drive the association of peptides into dimers.
  • portions of immunoglobulin gene sequences are used to drive the association of non-immunoglobulin peptides. These portions correspond to discrete domains of immunoglobulins. Immunoglobulins comprise variable and constant regions, which in turn comprise discrete domains that show similarity in their three-dimensional conformations.
  • immunoglobulin heavy chain constant region domain exons correspond to immunoglobulin heavy chain constant region domain exons, immunoglobulin heavy chain variable region domain exons, immunoglobulin light chain varable region domain exons and immunoglobulin light chain constant region domain exons in immunoglobulin genes (Hood et al., in Immunology, The Benjamin/Cummings Publishing Company, Inc., Menlo Park, Calif.; Honjo et al., Cell 18: 559-568, 1979; Takahashi et al., Cell 29: 671-679, 1982; and Honjo, Ann. Rev. Immun. 1:499-528, 1983)).
  • Particularly preferred portions of immunoqlobulin heavy chains include Fab and Fab' fragments.
  • An Fab fragment is a portion of an immunoglobulin heavy chain that includes a heavy chain variable region domain and a heavy chain constant region domain.
  • An Fab' fragment is a portion of an immunoglobulin heavy chain that includes a heavy chain variable region domain, a heavy chain constant region domain and a heavy chain hinge region domain.
  • an immunoglobulin light chain constant region in association with at least one immunoglobulin heavy chain constant region domain.
  • an immunoglobulin light chain constant region is associated with at least one immunoglobulin heavy chain constant region domain joined to an immunoglobulin hinge region.
  • an immunoglobulin light chain constant region joined in frame with a peptide dimer or receptor analog and is associated with at least one heavy chain constant region.
  • a variable region is joined upstream or and in proper reading frame with at least one immunoglobulin heavy chain constant region.
  • an immunoglobulin heavy chain is joined in frame with a peptide dimer or receptor analog and is associated with an immunoglobulin light chain constant region.
  • a peptide dimer or receptor analog joined to at least one immunoglobulin heavy chain constant region joined to an immunoglobulin hinge region and is associated with an immunoglobulin light chain constant region.
  • an immunoglobulin varable region is joined upstream of and in proper reading frame with the immunoglobulin light chain constant region.
  • Immunoglobulin heavy chain constant region domains include C H 1, C H 2, C H 3, and C H 4 of any class of Immunoglobulin heavy chain including ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ classes (Honjo, ibid., 1983)
  • a particularly preferred immunoglobulin heavy chain constant region domain is human C H 1.
  • Immunoglobulin variable regions include V H , V.sub. ⁇ , or V.sub. ⁇ .
  • DNA sequences encoding immunoglobulins may be cloned from a variety of genomic or cDNA libraries known in the art.
  • the techniques for isolating such DNA sequences are conventional techniques and are well known to those skilled in the art.
  • Probes for isolating such DNA sequences may be based on published DNA sequences (see, for example, Hieter et al., Cell 22: 197-207, 1980). The choice of library and selection of probes for the isolation of such DNA sequences is within the level of ordinary skill in the art.
  • Host cells for use in practicing the present invention include mammalian and fungal cells.
  • Fungal cells including species of yeast (e.g., Saccharomyces spp., Schizosaccharomyces spp.), or filamentous fungi (e.g., Aspergillus spp., Neurospora spp.) may be used as host cells within the present invention.
  • yeast e.g., Saccharomyces spp., Schizosaccharomyces spp.
  • filamentous fungi e.g., Aspergillus spp., Neurospora spp.
  • yeast Saccharomyces cerevisiae are particularly preferred.
  • Suitable yeast vectors for use in the present invention include YRp7 (Struhl et al., Proc. Natl. Acad. Sci. USA 76: 1035-1039, 1978), YEp13 (Broach et al., Gene 8: 121-133, 1979), pJDB249 and pJDB219 (Beggs, Nature 275:104-108, 1978) and derivatives thereof.
  • Such vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected.
  • Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include LEU2 (Broach et al. ibid.), URA3 (Botstein et al., Gene 8: 17, 1979), HIS3 (Struhl et al., ibid.) or POT1 (Kawasaki and Bell, EP 171,142).
  • LEU2 Bact et al. ibid.
  • URA3 Botstein et al., Gene 8: 17, 1979
  • HIS3 Struhl et al., ibid.
  • POT1 Yamasaki and Bell, EP 171,142
  • Other suitable selectable markers include the CAT gene, which confers chloramphenicol resistance on yeast cells.
  • promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255: 12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 1: 419-434, 1982; Kawasaki, U.S. Pat. No. 4,599,311) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals, Hollaender et al., (eds.), p. 355, Plenum, N.Y., 1982; Ammerer, Meth. Enzymol. 101: 192-201, 1983).
  • particularly preferred promoters are the TPI1 promoter (Kawasaki, U.S. Pat. No. 4,599,311, 1986) and the ADH2-4 c promoter (Russell et al., Nature 304: 652-654, 1983 and Irani and Kilgore, described in pending, commonly assigned U.S. patent application Ser. Nos. 029,867, now abandoned, and 183,130, now abandoned which are incorporated herein by reference).
  • the expression units may also include a transcriptional terminator.
  • a preferred transcriptional terminator is the TPI1 terminator (Alber and Kawasaki, ibid.).
  • proteins of the present invention can be expressed in filamentous fungi, for example, strains of the fungi Aspergillus (McKnight and Upshall, described in pending, commonly assigned U.S. patent application Ser. Nos. 820,519, now abandoned, and 946,873, now U.S. Pat. No. 4,035,349, corresponding to published European Patent Application EP 272,277, which are incorporated herein by reference).
  • useful promoters include those derived from Aspergillus nidulans glycolytic genes, such as the ADH3 promoter (McKnight et al., EMBO J. 4: 2093-2099, 1985) and the promoter.
  • ADH3 terminator An example of a suitable terminator is the ADH3 terminator (McKnight et al., ibid.).
  • the expression units utilizing such components are cloned into vectors that are capable of insertion into the chromosomal DNA of Aspergillus.
  • the genotype of the host cell will generally contain a qenetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.
  • a yeast host cell that contains a genetic deficiency in a gene required for asparagine-linked glycosylation of glycoproteins is used.
  • the yeast host cell contains a genetic deficiency in the MNN9 gene (described in pending, commonly assigned U.S. patent application Ser. Nos. 116,095 and 189,547 which are incorporated by reference herein in their entirety).
  • the yeast host cell contains a disruption of the MNN9 gene.
  • Yeast host cells having such defects may be prepared using standard techniques of mutation and selection. Ballou et al. (J. Biol. Chem.
  • mannoprotein biosynthesis mutants that are defective in genes which affect asparagine-linked glycosylation.
  • mutagenized yeast cells were screened using fluoresceinated antibodies directed against the outer mannose chains present on wild-type yeast. Mutant cells that did not bind antibody were further characterized and were found to be defective in the addition of asparagine-linked oligosaccharide moieties.
  • the host strain carries a mutation, such as the yeast pep4 mutation (Jones, Genetics 85: 23-33, 1977), which results in reduced proteolytic activity.
  • cultured mammalian cells may be used as host cells within the present invention.
  • Preferred cell lines are rodent myeloma cell lines, which include p3X63Ag8 (ATCC TIB 9), FO (ATCC CRL 1646), NS-1 (ATCC TIB 18) and 210-RCY-Ag1 (Galfre et al., Nature 277: 131, 1979).
  • a particularly preferred rodent myeloma cell line is SP2/0-Ag14 (ATCC CRL 1581).
  • COS-1 ATCC CRL 1650
  • BHK BHK
  • p363.Ag.8.653 ATCC CRL 1580
  • Rat Hep I ATCC CRL 1600
  • Rat Hep II ATCC CRL 1548
  • TCMK ATCC CCL 139
  • Human lung ATCC CCL 75.1
  • Human hepatoma ATCC HTB-52
  • Hep G2 ATCC HB 8065
  • Mouse liver ATCC CC 29.1
  • 293 ATCC CRL 1573; Graham et al., J. Gen. Virol. 36: 59-72, 1977
  • DUKX cells Urlaub and Chasin, Proc. Natl. Acad.
  • a preferred BHK cell line is the tk - ts13 BHK cell line (Waechter and Baserga, Proc. Natl. Acad. Sci USA 79: 1106-1110, 1982).
  • Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA.
  • Preferred promoters include viral promoters and cellular promoters.
  • Preferred viral promoters include the major late promoter from adenovirus 2 (Kaufman and Sharp, Mol. Cell. Biol. 2: 1304-13199, 1982) and the SV40 promoter (Subramani et al., Mol. Cell. Biol. 1: 854-864, 1981).
  • Preferred cellular promoters include the mouse metallothionein 1 promoter (Palmiter et al., Science 222: 809-814, 1983) and a mouse V.sub. ⁇ promoter (Grant et al., Nuc. Acids Res. 15: 5496, 1987).
  • a particularly preferred promoter is a mouse VH promoter (Loh et al., ibid.).
  • Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes.
  • polyadenylation signal located downstream of the coding sequence of interest.
  • Polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, ibid.), the polyadenylation signal from the adenovirus 5 EIB region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9: 3719-3730, 1981).
  • a particularly preferred polyadenylation signal is the VH gene terminator (Loh et al., ibid.).
  • the expression vectors may include a noncoding viral leader sequence, such as the adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites.
  • Preferred vectors may also include enhancer sequences, such as the SV40 enhancer and the mouse enhancer (Gillies, Cell 33: 717-728, 1983).
  • Expression vectors may also include sequences encoding the adenovirus VA RNAs.
  • Cloned DNA sequences may be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14: 725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7: 603, 1981; Graham and Van der Eb, Virology 52: 456, 1973.)
  • Other techniques for introducing cloned DNA sequences into mammalian cells such as electroporation (Neumann et al., EMBO J. 1: 841-845, 1982), may also be used.
  • a selectable marker is generally introduced into the cells along with the gene or cDNA of interest.
  • Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate.
  • the selectable marker may be an amplifiable selectable marker.
  • a preferred amplifiable selectable marker is the DHFR gene.
  • a particularly preferred amplifiable marker is the DHFR r cDNA (Simonsen and Levinson, Proc. Natl. Adac. Sci. USA 80: 2495-2499, 1983). Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, Mass.) and the choice of selectable markers is well within the level of ordinary skill in the art.
  • Selectable markers may be introduced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid. If on the same plasmid, the selectable marker and the gene of interest may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Pat. No. 4,713,339). It may also be advantageous to add additional DNA, known as "carrier DNA" to the mixture which is introduced into the cells.
  • carrier DNA additional DNA
  • Transfected mammalian cells are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels.
  • Host cells containing DNA constructs of the present invention are grown in an appropriate growth medium.
  • appropriate growth medium means a medium containing nutrients required for the growth of cells.
  • Nutrients required for cell growth may include a carbon source, a nitrogen source, essential amino acids, vitamins, minerals and growth factors.
  • the growth medium will generally select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient which are complemented by the selectable marker on the DNA construct or co-transfected with the DNA construct.
  • Yeast cells for example, are preferably grown in a chemically defined medium, comprising a non-amino acid nitrogen source, inorganic salts, vitamins and essential amino acid supplements.
  • the pH of the medium is preferably maintained at a pH greater than 2 and less than 8, preferably at pH 6.5.
  • Methods for maintaining a stable pH include buffering and constant pH control, preferably through the addition of sodium hydroxide.
  • Preferred buffering agents include succinic acid and Bis-Tris (Sigma Chemical Co., St. Louis, Mo.).
  • Yeast cells having a defect in a gene required for asparagine-linked glycosylation are preferably grown in a medium containing an osmotic stabilizer.
  • a preferred osmotic stabilizer is sorbitol supplemented into the medium at a concentration between 0.1M and 1.5M., preferably at 0.5M or 1.0M.
  • Cultured mammalian cells are generally grown in commercially available serum-containing or serum-free media. Selection of a medium appropriate for the particular cell line used is within the level of ordinary skill in the art.
  • the culture medium from appropriately grown transformed or transfected host cells is separated from the cell material, and the presence of peptide dimers or secreted receptor analogs is demonstrated.
  • a preferred method of detecting receptor analogs is by the binding of the receptors or portions of receptors to a receptor-specific antibody.
  • An anti-receptor antibody may be a monoclonal or polyclonal antibody raised against the receptor in question, for example, an anti-PDGF receptor monoclonal antibody may be used to assay for the presence of PDGF receptor analogs.
  • Another antibody which may be used for detecting substance P-tagged peptides and proteins, is a commercially available rat anti-substance P monoclonal antibody which may be utilized to visualize peptides or proteins that are fused to the C-terminal amino acids of substance P.
  • Ligand binding assays may also be used to detect the presence of receptor analogs.
  • PDGF receptor analogs it is preferable to use fetal foreskin fibroblasts, which express PDGF receptors, to compete against the PDGF receptor analogs of the present invention for labeled PDGF and PDGF isoforms.
  • Assays for detection of secreted, biologically active peptide dimers and receptor analogs may include Western transfer, protein blot or colony filter.
  • a Western transfer filter may be prepared using the method described by Towbin et al. (Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979). Briefly, samples are electrophoresed in a sodium dodecylsulfate polyacrylamide gel. The proteins in the gel are electrophoretically transferred to nitrocellulose paper. Protein blot filters may be prepared by filtering supernatant samples or concentrates through nitrocellulose filters using, for example, a Minifold (Schleicher & Schuell).
  • Colony filters may be prepared by growing colonies on a nitrocellulose filter that has been laid across an appropriate growth medium. In this method, a solid medium is preferred. The cells are allowed to grow on the filters for at least 12 hours. The cells are removed from the filters by washing with an appropriate buffer that does not remove the proteins bound to the filters.
  • a preferred buffer comprises 25 mM Tris-base, 19 mM glycine, pH 8.3, 20% methanol.
  • peptide dimers and receptor analogs present on the Western transfer, protein blot or colony filters may be visualized by specific antibody binding using methods known in the art.
  • Towbin et al. describe the visualization of proteins immobilized on nitrocellulose filters with a specific antibody followed by a labeled second antibody, directed against the first antibody.
  • Kits and reagents required for visualization are commercially available, for example, from Vector Laboratories, (Burlingame, Calif.), and Sigma Chemical Company (St. Louis, Mo.).
  • Secreted, biologically active peptide dimers and receptor analogs may be isolated from the medium of host cells grown under conditions that allow the secretion of the receptor analogs and biologically active peptide dimers.
  • the cell material is removed from the culture medium, and the biologically active peptide dimers and receptor analogs are isolated using isolation techniques known in the art. Suitable isolation techniques include precipitation and fractionation by a variety of chromatographic methods, including gel filtration, ion exchange chromatography and immunoaffinity chromatography.
  • a particularly preferred purification method is immunoaffinity chromatography using an antibody directed against the receptor analog or peptide dimer.
  • the antibody is preferably immobilized or attached to a solid support or substrate.
  • a particularly preferred substrate is CNBr-activated Sepharose (Pharmacia, Piscataway, N.J.).
  • the medium is combined with the antibody/substrate under conditions that will allow binding to occur.
  • the complex may be washed to remove unbound material, and the receptor analog or peptide dimer is released or eluted through the use of conditions unfavorable to complex formation.
  • Particularly useful methods of elution include changes in pH, wherein the immobilized antibody has a high affinity for the ligand at a first pH and a reduced affinity at a second (higher or lower) pH; changes in concentration of certain chaotropic agents; or through the use of detergents.
  • the secreted PDGF receptor analogs of the present invention can be used within a variety of assays for detecting the presence of native PDGF, PDGF isoforms or PDGF-like molecules. These assays will typically involve combining PDGF receptor analogs, which may be bound to a solid substrate such as polymeric microtiter plate wells, with a biological sample under conditions that permit the formation of receptor/ligand complexes. Detection may be achieved through the use of a label attached to the receptor or through the use of a labeled antibody which is reactive with the receptor. Alternatively, the labeled antibody may be reactive with the ligand. A wide variety of labels may be utilized, such as radionuclides, fluorophores, enzymes and luminescers. Complexes may also be detected visually, i.e., in immunoprecipitation assays, which do not require the use of a label.
  • Secreted PDGF receptor analogs of the present invention may also be labeled with a radioisotope or other imaging agent and used for in vivo diagnostic purposes.
  • Preferred radioisotope imaging agents include iodine-125 and technetium-99, with technetium-99 being particularly preferred.
  • Methods for producing protein-isotope conjugates are well known in the art, and are described by, for example, Eckelman et al. (U.S. Pat. No. 4,652,440), Parker et al. (WO 87/05030) and Wilber et al. (EP 203,764).
  • the secreted receptor analogs may be bound to spin label enhancers and used for magnetic resonance (MR) imaging.
  • MR magnetic resonance
  • Suitable spin label enhancers include stable, sterically hindered, free radical compounds such as nitroxides.
  • Methods for labeling ligands for MR imaging are disclosed by, for example, Coffman et al. (U.S. Pat. No. 4,656,026).
  • the labeled receptor analogs are combined with a pharmaceutically acceptable carrier or diluent, such as sterile saline or sterile water. Administration is preferably by bolus injection, preferably intravenously.
  • a pharmaceutically acceptable carrier or diluent such as sterile saline or sterile water.
  • Administration is preferably by bolus injection, preferably intravenously.
  • These imaging agents are particularly useful in identifying the locations of atherosclerotic plaques, PDGF-producing tumors, and receptor-bound PDGF.
  • the secreted PDGF receptor analogs of the present invention may also be utilized within diagnostic kits.
  • the subject receptor analogs are preferably provided in a lyophilized form or immobilized onto the walls of a suitable container, either alone or in conjunction with antibodies capable of binding to native PDGF or selected PDGF isoform(s) or specific ligands.
  • the antibodies which may be conjugated to a label or unconjugated, are generally included in the kits with suitable buffers, such as phosphate, stabilizers, inert proteins or the like. Generally, these materials are present in less than about 5% weight based upon the amount of active receptor analog, and are usually present in an amount of at least about 0.001% weight.
  • kits will typically include other standard reagents, instructions and, depending upon the nature of the label involved, reactants that are required to produce a detectable product.
  • an antibody capable of binding to the receptor or receptor/ligand complex is employed, this antibody will usually be provided in a separate vial.
  • the antibody is typically conjugated to a label and formulated in an analogous manner with the formulations briefly described above.
  • the diagnostic kits, including the containers, may be produced and packaged using conventional kit manufacturing procedures.
  • the secreted PDGF receptor analogs of the present invention may be utilized within methods for purifying PDGF from a variety of samples.
  • the secreted PDGF receptor analogs are immobilized or attached to a substrate or support material, such as polymeric tubes, beads, polysaccharide particulates, polysaccharide-containing materials, polyacrylamide or other water insoluble polymeric materials.
  • a substrate or support material such as polymeric tubes, beads, polysaccharide particulates, polysaccharide-containing materials, polyacrylamide or other water insoluble polymeric materials.
  • Methods for immobilization are well known in the art (Mosbach et al., U.S. Pat. No. 4,415,665; Clarke et al., Meth. Enzymology 68: 436-442, 1979).
  • a common method of immobilization is CNBr activation.
  • Activated substrates are commercially available from a number of suppliers, including Pharmacia (Piscataway, N.J.), Pierce Chemical Co. (Rockford, Ill. and Bio-Rad Laboratories (Richmond, Calif.).
  • a preferred substrate is CNBr-activated Sepharose (Pharmacia, Piscataway, N.J.).
  • the substrate/receptor analog complex will be in the form of a column.
  • the sample is then combined with the immobilized receptor analog under conditions that allow binding to occur.
  • the substrate with immobilized receptor analog is first equilibrated with a buffer solution of a composition in which the receptor analog has been previously found to bind its ligand.
  • the sample in the solution used for equilibration, is then applied to the substrate/receptor analog complex.
  • the complex is in the form of a column, it is preferred that the sample be passed over the column two or more times to permit full binding of ligand to receptor analog.
  • the complex is then washed with the same solution to elute unbound material.
  • a second wash solution may be used to minimize nonspecific binding.
  • the bound material may then be released or eluted through the use of conditions unfavorable to complex formation.
  • Particularly useful methods include changes in pH, wherein the immobilized receptor has a high affinity for PDGF at a first pH and reduced affinity at a second (higher or lower) pH; changes in concentration of certain chaotropic agents; or through the use of detergents.
  • the secreted PDGF receptor analogs fused to dimerizing proteins of the present invention may be used in pharmaceutical compositions for topical or intravenous application.
  • the PDGF receptor analogs fused to dimerizing proteins are used in combination with a physiologically acceptable carrier or diluent.
  • Preferred carriers and diluents include saline and sterile water.
  • Pharmaceutical compositions may also contain stabilizers and adjuvants.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • Enzymes including restriction enzymes, DNA polymerase I (Klenow fragment), T4 DNA polymerase, T4 DNA ligase and T4 polynucleotide kinase, were obtained from New England Biolabs (Beverly, Mass.), Bethesda Research Laboratories (Gaithersburg, Md.) and Boerhinger-Mannheim Biochemicals (Indianapolis, Ind.) and were used as directed by the manufacturer or as described in Maniatis et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1982).
  • cDNA libraries were prepared from poly(A) RNA from diploid human dermal fibroblast cells, prepared by explant from a normal adult, essentially as described by Hagen et al. (Proc. Natl. Acad. Sci. USA 83: 2412-2416, 1986). Briefly, the poly(A) RNA was primed with oligo(T) and cloned into kgt11 using Eco RI linkers. The random primed library was screened for the presence of human PDGF receptor cDNA's using three oligonucleotide probes complementary to sequences of the mouse PDGF receptor (Yarden et al., Nature 323: 226-232, 1986).
  • RP41 and RP51 were selected for further analysis by restriction enzyme mapping and DNA sequence analysis. RP51 was found to contain 356 bp of 5'-noncoding sequence, the ATG translation initiation codon and 738 bp of the amino terminal coding sequence. RP41 was found to overlap clone RP51 and contained 2649 bp encoding amino acids 43-925 of the receptor protein.
  • the 3'-end of the cDNA was not isolated in the first cloning and was subsequently isolated by screening 6 ⁇ 10 5 phage of the oligo (dT)-primed cDNA library with a 630 bp Sst I-Eco RI fragment derived from the 3'-end of clone RP41.
  • Clones RP51, RP41 and OT91 were ligated together to construct a full-length cDNA encoding the entire PDGF receptor.
  • RP41 was digested with Acc I and Bam HI to isolate the 2.12 kb fragment.
  • RP51 was digested with Eco RI and Acc I to isolate the 982 bp fragment.
  • the 2.12 kb RP41 fragment and the 982 bp RP51 fragment were joined in a three-part ligation with pUC13, which had been linearized by digestion with Eco RI and Bam HI.
  • the resultant plasmid was designated 51/41.
  • plasmid 51/41 was digested with Eco RI and Bam HI to isolate the 3 kb fragment comprising the partial PDGF receptor cDNA.
  • OT91 was digested with Bam HI and Xba I to isolate the 1.4 kb fragment containing the 3' portion of the PDGF receptor cDNA.
  • the Eco RI-Bam HI 51/41 fragment, the Bam HI-Xba I OT91 fragment and the Eco RI-Xba I digested pUC13 were joined in a three-part ligation.
  • the resultant plasmid was designated pR-RXI (FIG. 2).
  • the PDGF receptor cDNA was joined to a sequence encoding the Saccharomvces cerevisiae SUC2 signal sequence.
  • Oligonucleotides ZC1453 and ZC1454 (Table 1) were designed to form an adapter encoding the SUC2 secretory signal flanked by a 5' Eco RI adhesive end and a 3, Bgl II adhesive end.
  • ZC1453 and ZC1454 were annealed under conditions described by Maniatis et al. (ibid.).
  • Plasmid pR-RX1 was digested with Bgl II and Sst II to isolate the 1.7 kb fragment comprising the PDGF receptor coding sequence from amino acids 28 to 596. Plasmid pR-RX1 was also cut with Sst II and Hind III to isolate the 1.7 kb fragment comprising the coding sequence from amino acids 597 through the translation termination codon and 124 bp of 3' untranslated DNA. The two 1.7 kb pR-RX1 fragments and the ZC1453/ZC1454 adapter were joined with pUC19, which had been linearized by digestion with Eco RI and Hind III. The resultant plasmid, comprising the SUC2 signal sequence fused in-frame with the PDGF receptor cDNA, was designated pBTL10 (FIG. 2).
  • the BAR1 gene product, Barrier is an exported protein that has been shown to have three domains. When used in conjunction with a first signal sequence, the third domain of Barrier protein has been shown to aid in the secretion of proteins into the medium (MacKay et al., U.S. patent application Ser. No. 104,316).
  • the portion of the BAR1 gene encoding the third domain of Barrier was joined to a sequence encoding the C-terminal portion of substance P (subP; Munro and Pelham, EMBO J. 3: 3087-3093, 1984).
  • substance P substance P amino acids on the terminus of the fusion protein allowed the protein to be detected using commercially available anti-substance P antibodies.
  • Plasmid pZV9 deposited as a transformant in E. coli strain RR1, ATCC accession no. 53283
  • Plasmid pZV17 was digested with Eco RI to remove the 3'-most 0.5 kb of the BAR1 coding region.
  • the vector-BAR1 fragment was religated to create the plasmid designated pJH66 (FIG. 3).
  • Plasmid pJH66 was linearized with Eco RI and blunt-ended with DNA polymerase I (Klenow fragment).
  • Kinased Bam HI linkers (5' CCG GAT CCG G 3') were added and excess linkers were removed by digestion with Bam HI before religation.
  • the resultant plasmid was designated pSW8 (FIG. 3).
  • Plasmid pSW81 comprising the promoter, the BAR1 coding region fused to the coding region of the C-terminal portion of substance P (Munro and Pelham, EMBO J. 3: 3087-3093, 1984) and the TPI1 terminator, was derived from pSW8. Plasmid pSW8 was cut with Sal I and Bam HI to isolate the 824 bp fragment encoding amino acids 252 through 526 of BAR1. Plasmid pPM2, containing the synthetic oligonucleotide sequence encoding the dimer form of the C-terminal portion of substance P (subP) in M13mp8, was obtained from Hugh Pelham (MRC Laboratory of Molecular Biology, Cambridge, England).
  • Plasmid pPM2 was linearized by digestion with Bam HI and Sal I and ligated with the 824 bp BAR1 fragment from pSW8.
  • the resultant plasmid, pSWI4 was digested with Sal I and Sma I to isolate the 871 bp BAR1-substance P fragment.
  • Plasmid pSW16 comprising a fragment of BAR1 encoding amino acids 1 through 250, was cut with Xba I and Sal I to isolate the 767 bp BAR1 fragment. This fragment was ligated with the 871 bp BAR1-substance P fragment in a three-part ligation with pUC18 cut with Xba I and Sma I.
  • the resultant plasmid was digested with Xba I and Sma I to isolate the 1.64 kb BAR1-substance P fragment.
  • the ADH1 promoter was obtained from pRL029.
  • Plasmid pRL029 comprising the ADH1 promoter and the BAR15' region encoding amino acids 1 to 33 in pUC18, was digested with Sph I and Xba I to isolate the 0.42 kb ADH1 promoter fragment.
  • the TPI1 terminator (Alber and Kawasaki, ibid.) was provided as a linearized fragment containing the TPI1 terminator and pUC18 with a Klenow-filled Xba I end and an Sph I end. This fragment was ligated with the 0.42 kb ADH1 promoter fragment and the 1.64 kb BAR1-substance P fragment in a three-part ligation to produce plasmid pSW22.
  • Oligonucleotide ZC1478 (Table 1) was kinased and annealed with oligonucleotide ZC1479 (Table 1) using conditions described by Maniatis et al. (ibid.).
  • the annealed oligonucleotides formed an adapter comprising a Hind III adhesive end and a polylinker encoding Bgl II, Sph I, Nru I and Eco RV restriction sites.
  • the ZC1479/ZC1478 adapter was ligated with the gel-purified pSW22 fragment.
  • the resultant plasmid was designated pCBS22 (FIG. 3).
  • Plasmid pBTL10 (Example 2) was digested with Sph I and Sst I to isolate the 4 kb fragment comprising the SUC2 signal sequence, a portion of the PDGF receptor cDNA and the pUC19 vector sequences. Plasmid pCBS22 was digested with Sph I and Sst I to isolate the 1.2 kb fragment comprising the BAR1-subP fusion and the TPI1 terminator. These two fragments were ligated, and the resultant plasmid was designated pBTL13 (FIG. 4).
  • the entire PDGF receptor was directed into the secretory pathway by fusing a SUC2 signal sequence to the 5' end of the PDGF receptor coding sequence. This fusion was placed behind the TPI1 promoter and inserted into the vector YEp13 for expression in yeast.
  • the TPI1 promoter was obtained from plasmid pTPIC10 (Alber and Kawasaki, J. Mol. Appl. Genet. 1: 410-434, 1982), and plasmid pFATPOT (Kawasaki and Bell, EP 171,142; ATCC 20699). Plasmid pTPIC10 was cut at the unique Kpn I site, the coding region was removed with Bal-31 exonuclease, and an Eco RI linker (sequence: GGA ATT CC) was added to the 3, end of the promoter. Digestion with Bgl II and Eco RI yielded a TPI1 promoter fragment having Bgl II and Eco RI sticky ends.
  • Plasmid TEA32 was digested with Bgl II and Eco RI, and the 900 bp partial TPI1 promoter fragment was gel-purified.
  • Plasmid pIC19H (Marsh et al., Gene 32:481-486, 1984) was cut with Bgl II and Eco RI and the vector fragment was gel purified. The TPI1 promoter fragment was then ligated to the linearized pIC19H and the mixture was used to transform E. coli RR1. Plasmid DNA was prepared and screened for the presence of a ⁇ 900 bp Bgl II-Eco RI fragment. A correct plasmid was selected and designated pICTPIP.
  • Plasmid pIC7 (Marsh et al., ibid.) was digested with Eco RI, the fragment ends were blunted with DNA polymerase I (Klenow fragment), and the linear DNA was recircularized using T4 DNA ligase. The resulting plasmid was used to transform E. coli RR1. Plasmid DNA was prepared from the transformants and was screened for the loss of the Eco RI site. A plasmid having the correct restriction pattern was designated pIC7RI*. Plasmid pIC7RI* was digested with Hind III and Nar I, and the 2500 bp fragment was gel-purified.
  • the partial TPI1 promoter fragment (ca. 900 bp) was removed from pICTPIP using Nar I and Sph I and was gel-purified.
  • the remainder of the TPI1 promoter was obtained from plasmid pFATPOT by digesting the plasmid with Sph I and Hind III, and a 1750 bp fragment, which included a portion of the TPI1 promoter fragment from pICTPIP, and the fragment from pFATPOT were then combined in a triple ligation to produce pMVR1 (FIG. 2).
  • the TPI1 promoter was then joined to the SUC2-PDGF receptor fusion.
  • Plasmid pBTL10 (Example 2) was digested with Eco RI and Hind III to isolate the 3.4 kb fragment comprising the SUC2 signal sequence and the entire PDGF receptor coding region.
  • Plasmid pMVR1 was digested with Bgl II and Eco RI to isolate the 0.9 kb TPI1 promoter fragment.
  • the TPI1 promoter fragment and the fragment derived from pBTL10 were joined with YEp13, which had been linearized by digestion with Bam HI and Hind III, in a three-part ligation.
  • the resultant plasmid was designated pBTL12 (FIG. 2).
  • the extracellular portion of the PDGF receptor was directed into the secretory pathway by fusing the coding sequence to the signal sequence. This fusion was placed in an expression vector behind the TPI1 promoter.
  • Plasmid pBTL10 (Example 2) was digested with Eco RI and Sph I to isolate the approximately 1.3 kb fragment comprising the SUC2 signal sequence and the PDGF receptor extracellular domain coding sequence.
  • Plasmid pMVR1 (Example 5) was digested with Bgl II and Eco RI to isolate the 0.9 kb TPI1 promoter fragment.
  • the TPI1 promoter fragment was joined with the fragment derived from pBTL10 and YEp13, which had been linearized by digestion with Bam HI and Sph I, in a three-part ligation.
  • the resultant plasmid was designated pBTLll (FIG. 2).
  • the SUC2-PDGF-R fusion was joined with the third domain of BAR1 to enhance the secretion of the receptor, and the expression unit was cloned into a derivative of YEp13 termed pJH50.
  • YEp13 was modified to destroy the Sal I site near the LEU2 gene. This was achieved by partially digesting YEp13 with Sal I followed by a complete digestion with Xho I. The 2.0 kb Xho I-Sal I fragment comprising the LEU2 gene and the 8.0 kb linear YEp13 vector fragment were isolated and ligated together. The ligation mixture was transformed into E. coli strain RR1. DNA was prepared from the transformants and was analyzed by digestion with Sal I and Xho I.
  • a clone was isolated which showed a single Sal I site and an inactive Xho I site indicating that the LEU2 fragment had inserted in the opposite orientation relative to the parent plasmid YEp13.
  • the plasmid was designated pJH50.
  • Plasmid pBTL12 (Example 5) was digested with Sal I and Pst I to isolate the 2.15 kb fragment comprising 270 bp of YEp13 vector sequence, the TPI1 promoter, the SUC2 signal sequence, and 927 bp of PDGF receptor cDNA.
  • Plasmid pBTL13 (Example 4) was digested with Pst I and Hind III to isolate the 1.48 kb fragment comprising 313 bp of PDGF receptor cDNA, the BAR1-subP fusion and the TPI1 terminator.
  • the fragments derived from pBTL12 and pBTL13 were joined with pJH50, which had been linearized by digestion with Hind III and Sal I, in a three-part ligation.
  • the resultant plasmid was designated pBTL14.
  • a yeast expression vector was constructed comprising the TPI1 promoter, the SUC2 signal sequence, 1.45 kb of PDGF receptor cDNA sequence fused to the fusion and the TPI1 terminator.
  • Plasmid pBTL12 (Example 5) was digested with Sal I and Fsp I to isolate the 2.7 kb fragment comprising the TPI1 promoter, the SUC2 signal sequence, the PDGF-R coding sequence, and 270 bp of YEp13 vector sequence.
  • Plasmid pBTL13 (Example 4) was digested with Nru I and Hind III to isolate the 1.4 kb fragment comprising the BAR1-subP fusion, the TPI1 terminator and 209 bp of 3' PDGF receptor cDNA sequence.
  • the fragments derived from pBTL12 and pBTL13 were joined in a three-part ligation with pJH50, which had been linearized by digestion with Hind III and Sal I.
  • the resultant plasmid was designated pBTL15.
  • Yeast expression vectors pBTL14 and pBTL15 were transformed into Saccharomvces cerevisiae strains ZY100 (MATa leu2-3,112 ade2-101 suc2- ⁇ 9 gal2 pep4::TPI1prom-CAT) and ZY400 (MATa leu2-3, 112 ade2-101 suc2- ⁇ 9 gal2 pep4::TPI1prom-CAT ⁇ mnn9::URA3). Transformations were carried out using the method essentially described by Beggs (ibid.). Transformants were selected for their ability to grow on -LEUDS (Table 2).
  • the transformants were assayed for binding to an anti-PDGF receptor monoclonal antibody (PR7212) or an anti-substance P antibody by protein blot assay.
  • ZY100[pBTL14] and ZY100[pBTL15] transformants were grown overnight at 30° C. in 5 ml Super Synthetic -LEUD, pH 6.4 (Table 2).
  • ZY400[pBTL14] and ZY400[pBTL15] transformants were grown overnight at 30° C. in 5 ml Super Synthetic -LEUDS, pH 6.4 (Table 2).
  • the cultures were pelleted by centrifugation and the supernatants were assayed for the presence of secreted PDGF receptor anlogs by protein blot assay using methods described in Example 13. Results of assays using PR7212 are shown in Table 3.
  • the PDGF-R coding sequence present in pBTLI10 was modified to delete the coding region 3' to the extracellular PDGF-R domain.
  • plasmid pBTL10 was digested with Sph I and Bam HI and with Sph I and Sst II to isolate the 4.77 kb fragment and the 466 bp fragment, respectively.
  • the 466 bp fragment was then digested with Sau 3A to isolate the 0.17 kb fragment.
  • the 0.17 kb fragment and the 4.77 kb were joined by ligation.
  • the resultant plasmid was designated pBTL21.
  • Plasmid pBTL21 containing a Bam HI site that was regenerated by the ligation of the Bam HI and Sau 3A sites, was digested with Hind III and Bam HI to isolate the 4.2 kb fragment.
  • Synthetic oligonucleotides ZC1846 (Table 1) and ZC1847 (Table 1) were designed to form an adapter encoding the PDGF-R from the Sau 3A site after bp 1856 (FIG. 1) to the end of the extracellular domain at 1958 bp (FIG. 1), having a 5, Bam HI adhesive end that destroys the Bam HI site and a 3, Hind III adhesive end.
  • Oligonucleotides ZC1846 and ZC1847 were annealed under conditions described by Maniatis et. al. (ibid.).
  • the 4.2 pBTL21 fragment and the ZC1846/ZC1847 adapter were joined by ligation.
  • the resultant plasmid, designated pBTL22 comprises the SUC2 signal sequence fused in proper reading frame to the extracellular domain of PDGF-R in the vector pUC19 (FIG. 6).
  • Plasmid pMVRI was digested with Eco RI and Xba I to isolate the 3.68 kb fragment comprising the TPI1 promoter, pIC7RI* vector sequences and the TPI1 terminator. Oligonucleotides ZC1892 and ZC1893 were annealed to form a Hind III-Xba I adapter. The 1.6 kb SUC2-PDGF-R fragment, the 3.86 kb pMVRI fragment and the ZC1892/ZC1893 adapter were joined in a three-part ligation. The resultant plasmid was designated pBTL27.
  • the expression unit present in pBTL27 was inserted into the yeast expression vector pJH50 by first digesting pJH50 with Bam HI and Sal I to isolate the 10.3 kb vector fragment. Plasmid pBTL27 was digested with Bgl II and Eco RI and with Xho I and Eco RI to isolate the 0.9 kb TPI1 promoter fragment and the 1.65 kb fragment, respectively. The 10.3 kb pJH50 vector fragment, the 0.9 kb TPI1 promoter fragment and 1.65 kb fragment were joined in a three-part ligation. The resultant plasmid was designated pBTL28.
  • Plasmid pBTL22 was digested with Eco RI and Hind III to isolate the 1.6 kb SUC2-PDGF-R fragment. Plasmid pMVR1 was digested with Eco RI and Xba I to isolate the 3.68 kb fragment comprising the TPI1 promoter, pIC7RI* and the TPI1 terminator.
  • Synthetic oligonucleotides ZC1894 (Table 1) and ZC1895 (Table 1) were annealed to form an adapter containing the codons for the twelve C-terminal amino acids of substance P followed by an in-frame stop codon and flanked on the 5, end with a Hind III adhesive end and on the 3' end with an Xba I adhesive end.
  • the ZC1894/ZC1895 adapter, the 1.6 kb SUC2-PDGF-R fragment and the pMVRI fragment were joined in a three-part ligation.
  • the resultant plasmid designated pBTL29, was digested with Eco RI and Xho I to isolate the 1.69 kb SUC2-PDGF-R-subP-TPI1 terminator fragment.
  • Plasmid pBTL27 was digested with Bgl II and Eco RI to isolate the 0.9 kb TPI1 promoter fragment.
  • Plasmid pJH50 was digested with Bam HI and Sal I to isolate the 10.3 kb vector fragment.
  • the 1.69 kb pBTL29 fragment, the 0.9 kb TPI1 promoter fragment and the 10.3 kb vector fragment were joined in a three-part ligation.
  • the resulting plasmid was designated pBTL30.
  • Plasmid pBTL22 was digested with Eco RI and Hind III to isolate the 1.56 kb fragment.
  • Plasmid pMVRI was digested with Eco RI and Xba I to isolate the 3.7 kb fragment, comprising the TPI1 promoter, pIC7RI* vector sequences and the TPI1 terminator.
  • Oligonucleotides ZC1776 (Table 1) and ZC1777 (Table 1) were designed to form, when annealed, an adapter encoding an immunoglobulin hinge region with a 5, Hind III adhesive end and a 3, Xba I adhesive end. Oligonucleotides ZC1776 and ZC1777 were annealed under conditions described by Maniatis et al. (ibid.). The 1.56 kb pBTL22 fragment, the 3.7 kb fragment and the ZC1776/ZC1777 adapter were joined in a three-part ligation, resulting in plasmid pBTL24.
  • Plasmid pBTL24 comprising the TPI1 promoter, SUC2 signal sequence, PDGF-R extracellular domain sequence, hinge region sequence, and TPI1 terminator, was inserted into pJH50.
  • Plasmid pBTL24 was digested with Xho I and Hind III to isolate the 2.4 kb expression unit.
  • Plasmid pJH50 was digested with Hind III and Sal I to isolate the 9.95 kb fragment.
  • the 2.4 kb pBTL24 fragment and 9.95 kb pJH50 vector fragment were joined by ligation.
  • the resultant plasmid was designated pBTL25.
  • Plasmid pBTL25 was transformed into Saccharomyces cerevisiae strain ZY400 using the method essentially described by Beggs (ibid.). Transformants were selected for their ability to grow on -LEUDS (Table 2). The transformants were tested for their ability to bind the anti-PDGF-R monoclonal antibody PR7212 using the colony assay method described in Example 13. Plasmid pBTL25 transformants were patched onto nitrocellulose filters that had been wetted and supported by YEPD solid medium. Antibody PR7212 was found to bind to the PDGF-R-IgG hinge fusion secreted by ZY400[pBTL25] transformants.
  • an expression unit comprising the TPI1 promoter, SUC2 signal sequence, PDGF-R extracellular domain sequence, and SUC2 coding sequence was constructed as follows. Plasmid pBTL22 was digested with Eco RI and Hind III to isolate the 1.6 kb SUC2-PDGF-R fragment. Plasmid pMVRl was digested with Bgl II and Eco RI to isolate the 0.9 kb TPI1 promoter fragment. The SUC2 coding region was obtained from pJH40.
  • Plasmid pJH40 was constructed by inserting the 2.0 kb Hind III-Hind III SUC2 fragment from pRB58 (Carlson et al., Cell 28:145-154, 1982) into the Hind III site of pUC19 followed by the destruction of the Hind III site 3' to the coding region. Plasmid pJH40 was digested with Hind III and Sal I to isolate the 2.0 kb SUC2 coding sequence. Plasmid pJH50 was digested with Sal I and Bam HI to isolate the 10.3 kb vector fragment.
  • the resultant plasmid was designated pBTL26 (FIG. 6).
  • Plasmid pBTL26 was transformed into Saccharomyces cerevisae strain ZY400 using the method essentially described by Beggs (ibid.). Transformants were selected for their ability to grow on -LEUDS (Table 2). ZY400 transformants (ZY400[pBTL26]) were assayed by protein blot (Example 13), colony blot (Example 13) and competition assay.
  • Protein blot assays were carried out on ZY400[pBTL26] and ZY400[pJH50] (control) transformants that had been grown in flasks.
  • Two hundred-fifty ⁇ l of a 5 ml overnight cultures of ZY400[pBTL26] in -LEUDS+sodium succinate, pH 6.5 (Table 2) were inoculated into 50 ml of -LEUDS+ sodium succinate, pH 6.5.
  • the cultures were incubated for 35 hours in an airbath shaker at 30° C.
  • the culture supernatants were harvested by centrifugation.
  • the culture supernatants were assayed as described in Example 13 and were found to bind PR7212 antibody.
  • Colony assays were carried out on ZY400[pBTL26] transformants.
  • ZY400[pBTL26] transformants were patched onto wetted nitrocellulose filters that were supported on a YEPD plate.
  • the colony assay carried out as described in Example 13.A. showed that ZY400[pBTL26] antibodies bound PR7212 antibodies.
  • the competition binding assay measured the amount of 125I-PDGF left to bind to fetal foreskin fibroblast cells after preincubation with the concentrate containing the PDGF-R-SUC2 fusion protein.
  • the concentrate was serially diluted in binding medium (Table 4).
  • the dilutions were mixed with 0.5 ng of iodinated PDGF-AA, PDGF-BB or PDGF-AB, and the mixtures were incubated for two hours at room temperature. Three hundred ⁇ g of unlabeled PDGF-BB was added to each sample mixture.
  • the sample mixtures were added to 24-well plates containing confluent fetal foreskin fibroblast cells (AG1523, available from the Human Genetic Mutant Cell Repository, Camden, N.J.). The cells were incubated with the mixture for four hours at 4° C. The supernatants were aspirated from the wells, and the wells were rinsed three times with phosphate buffered saline that was held at 4+ C. (PBS; Sigma, St. Louis, Mo.). Five hundred ⁇ l of PBS+1% NP-40 was added to each well, and the plates were shaken on a platform shaker for five minutes. The cells were harvested and the amount of iodinated PDGF was determined. The results of the competition binding assay showed that the PDGF-R-SUC2 fusion protein was able to competetively bind all three isoforms of PDGF.
  • AG1523 available from the Human Genetic Mutant Cell Repository, Camden, N.J.
  • the PDGF-R produced from ZY400 [pBTL26] transformants was tested for cross reactivity to fibroblast growth factor (FGF) and transforming growth factor- ⁇ (TGF- ⁇ ) using the competition assay essentially described above.
  • FGF fibroblast growth factor
  • TGF- ⁇ transforming growth factor- ⁇
  • Supernatant concentrates from ZY400 [pBTL26] and ZY400 [JH50] (control) transformants were serially diluted in binding medium (Table 4). The dilutions were mixed with 7.9 ng of iodinated FGF or 14 L 25 ng of iodinated TGF- ⁇ , and the mixtures were incubated for two hours at room temperature.
  • the Tris, EDTA, NP-40 and NaCl were diluted to a final volume of one liter with distilled water.
  • the gelatin was added to 300 ml of this solution and the solution was heated in a microwave until the gelatin was in solution.
  • the gelatin solution was added back to the remainder of the first solution and stirred at 4° C. until cool.
  • the buffer was stored at 4° C.
  • the Tris, EDTA, NP-40, and the NaCl were mixed and diluted to a final volume of one liter.
  • the gelatin was added to 300 ml of this solution and heated in a microwave until the gelatin was in solution.
  • the gelatin solution was added back to the original solution and the N-lauroyl sarcosine was added.
  • the final mixture was stirred at 4° C. until the solids were completely dissolved. This buffer was stored at 4° C.
  • Plasmids pBTL14 and pBTL15 were digested with Eco RI to isolate the 1695 bp and 1905 bp SUC2 signal-PDGF-R-BAR1 fragments.
  • the 1695 bp fragment and the 1905 bp fragment were each ligated to ZEM229R that had been linearized by digestion with Eco RI.
  • Plasmid ZEM229 is a pUC18-based expression vector containing a unique Bam HI site for insertion of cloned DNA between the mouse metallothionein-1 promoter and SV40 transcription terminator and an expression unit containing the SV40 early promoter, mouse dihydrofolate reductase gene, and SV40 transcription terminator. Zem229 was modified to delete the Eco RI sites flanking the Bam HI cloning site and to replace the Bam HI site with a single Eco RI cloning site.
  • the plasmid was partially digested with Eco RI, treated with DNA polymerase I (Klenow fragment) and dNTPs, and religated. Digestion of the plasmid with Bam HI followed by ligaion of the linearized plasmid with a Bam HI-Eco I adapter resulted in a unique Eco RI cloning site.
  • the resultant plasmid was designated Zem229R.
  • Plasmid DNA was prepared and the plasmids were subjected to restriction enzyme analysis.
  • a plasmid having the 1695 bp pBTL14 fragment inserted into Zem229 R in the correct orientation was designated pBTL114 (FIG. 9).
  • a plasmid having the 1905 bp pBTL15 fragment inserted into Zem229R in the correct orientation was designated pBTL115 (FIG. 9).
  • Plasmids pBTL114 and pBTL115 were each transfected into tk - ts13 cells using calcium phosphate preciptation (essentially as described by Graham and van der Eb, J. Gen. Virol. 36: 59-72, 1977).
  • the transfected cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 1 ⁇ PSN antibiotic mix (Gibco 600-5640). 2.0 mM L-glutamine.
  • DMEM Dulbecco's modified Eagle's medium
  • the cells were selected in 250 nM methotrexate (MTX) for 14 days, and the resulting colonies were screened by the immunofilter assay (McCracken and Brown, Biotechnioues, 82-87, Mar./Apr.
  • the immunoglobulin ⁇ heavy chain promoter and enhancer were sublconed into pIC19H to provide a unique Hind III site 3' to the promoter.
  • Plasmid p ⁇ (Grosschedl and Baltimore, Cell 41: 885-897, 1985) was digested with Sal I and Eco RI to isolate the 3.1 kb fragment comprising the ⁇ promoter.
  • Plasmid pIC19H was linearized by digestion with Eco RI and Xho I.
  • the ⁇ promoter fragment and the linearized pIC19H vector fragment were joined by ligation.
  • the resultant plasmid, designated pIC ⁇ 3 was digested with Ava II to isolate the 700 bp promoter fragment.
  • Plasmid pIC19H was linearized by digestion with Xho I, and the adhesive ends were filled in by treatment with DNA polymerase I (Klenow fragement) and deoxynucleotide triphosphates.
  • the blunt-ended Ava II fragment was ligated with the blunt-ended, linearized pIC19H, and the ligation mixture was transformed into E. coli JM83.
  • Plasmid DNA was prepared from the transformants and was analyzed by restriction digest. A plasmid with a Bgl II site 5, to the promoter was designated pIC ⁇ PR1(-).
  • Plasmid pIC ⁇ PR1(-) was digested with Hind III and Bgl II to isolate the 700 bp promoter fragment. Plasmid pIC19R was linearized by digestion with Hind III and Bam HI. The 700 bp promoter fragment was joined with the linearized pIC19R by ligation.
  • the resultant plasmid, designated pIC ⁇ PR7 comprised the ⁇ promoter with an unique Sma I site 5, to the promoter and a unique Hind III site 3, to the promoter.
  • the immunoglobulin heavy chain ⁇ enhancer (Gillies et al., Cell 33: 717-728, 1983) was inserted into the unique Sma I site to generate plasmid pIC ⁇ PRE8.
  • Plasmid pJ4 (obtained from F. Blattner, Univ. Wisconsin, Madison, Wis.), comprising the 1.5 kb Hind III-Eco RI ⁇ enhancer fragment in the vector pAT153 (Amersham, Arlington Heights, Ill.), was digested with Hind III and Eco RI to isolate the 1.5 kb enhancer fragment.
  • the adhesive ends of the enhancer fragment were filled in by treatment with T4 DNA polymerase and deoxynucleotide triphosphates.
  • the DNA sequence encoding the extracellular domain of the PDGF receptor was joined with the DNA sequence encoding the human immunoglobulin light chain constant region.
  • the PDGF extracellular domain was obtained from mpBTL22, which comprised the Eco RI-Hind III fragment from pBTL22 (Example 8.A.) cloned into Eco RI-Hind III cut M13mp18.
  • Single stranded DNA was prepared from a mpBTL22 phage clone, and the DNA was subjected to vitro mutagenesis using the oligonucleotide ZC1886 (Table 1) and the method described by Kunkel (Proc. Natl. Acad. Sci. USA 82: 488-492, 1985).
  • a phage clone comprising the mutagenized PDGF-R with a donor splice site (5' splice site) at the 3' end of the PDGF-R extracellular domain was designated pBTLR-HX (FIG. 7).
  • the native PDGF-R signal sequence was obtained from pPR5.
  • Plasmid pPR5 comprising 738 bp of 5' coding sequence with an Eco RI site immediately 5' to the translation initiation codon, was constructed by in vitro mutagenesis of the PDGF-R cDNA fragment from RP51 (Example 1). Replicative form DNA of RP51 was digested with Eco RI to isolate the 1.09 kb PDGF-R fragment. The PDGF-R fragment was cloned into the Eco RI site of M13mp18. Single stranded template DNA was prepared from a phage clone containing the PDGF-R fragment in the proper orientation.
  • the template DNA was subjected to in vitro mutagenesis using oligonucleotide ZC1380 (Table 1) and the method described by Zoller and Smith (Meth. Enzymol. 100: 468-500, 1983).
  • the mutagenesis resulted in the placement of an Eco RI site immediately 5' to the translation initiation codon.
  • Mutagenized phage clones were analyzed by dideoxy sequence analysis.
  • a phage clone containing the ZC1380 mutation was selected and replicative form (Rf) DNA was prepared from the phage clone.
  • the Rf DNA was digested with Eco RI and Acc I to isolate the 0.63 kb fragment.
  • Plasmid pR-RXI (Example 1) was digested with Acc I and Eco RI to isolate the 3.7 kb fragment. The 0.63 kb fragment and the 3.7 kb fragment were joined by ligation resulting in plasmid pPR5 (FIG. 7).
  • the PDGF-R signal peptide and part of the extracellular domain were obtained from plasmid pPR5 as a 1.4 kb Eco RI-Sph I fragment.
  • Replicative form DNA from phage clone pBTLR-HX was digested with Sph I and Hind III to isolate the approximately 0.25 kb PDGF-R fragment.
  • Plasmid pUC19 was linearized by digestion with Eco RI and Hind III.
  • the 1.4 kb Eco RI-Sph I PDGF-R fragment, the 0.25 kb Sph I-Hind III fragment from pBTLR-HX and the Eco RI-Hind III cut pUC19 were joined in a three-part ligation.
  • the resultant plasmid, pSDL110 was digested with Eco RI and Hind III to isolate the 1.65 kb PDGF-R fragment.
  • Plasmid pICHuC k 3.9.11 was used as the source of the human immunoglobulin light chain gene (FIG. 7).
  • the human immunoglobulin light chain gene was isolated from a human genomic library using an oligonucleotide probe (5' TGT GAC ACT CTC CTG GGA GTT A 3'), which was based on a published human kappa C gene sequence (Hieter et al., Cell 22: 197-207, 1980).
  • the human light chain (kappa) constant region was subcloned as a 1.1 kb Sph I-Hinf I genomic fragment of the human kappa gene, which has been treated with DNA polymerase DNA I (Klenow Fragment) to fill in the Hinf I adhesive end, into Sph I-Hinc II cut pUC19.
  • the 1.1 kb human kappa constant region was susbsequently isolated as a 1.1 kb Sph I-Bam HI fragment that was subcloned into Sph I-Bgl II cut pIC19R (Marsh et al., ibid.).
  • the resultant plasmid was designated pICHuC k 3.9.11.
  • Plasmid pICHuC k 3.9.11 was digested with Hind III and Eco RI to isolate the 1.1 kb kappa constant region gene. Plasmid pIC19H was linearized by digestion with Eco RI. The 1.65 kb PDGF-R fragment, the 1.1 kb human kappa constant region fragment and the linearized pIC19H were joined in a three part ligation.
  • the resultant plasmid, pSDL112 was digested with Bam HI and Cla I to isolate the 2.75 kb fragment.
  • Plasmid p ⁇ PRE8 was linearized with Bgl II and Cla I. The 2.75 kb fragment and the linearized p ⁇ PRE8 were joined by ligation. The resultant plasmid was designated pSDL114 (FIG. 7).
  • Plasmid pSDL114 was linearized by digestion with Cla I and was cotransfected with Pvu I-digested p416 into SP2/0-Ag14 (ATCC CRL 1581) by electroporation using the method essentially described by Neumann et al. (EMBO J. 1: 841-845, 1982).
  • Plasmid p416 comprises the Adenovirus 5 ori, SV40 enhancer, Adenovirus 2 major late promoter, Adenovirus 2 tripartite leader, 5' and 3' splice sites, the DHFR r cDNA, the SV40 polyadenylation signal and pML-1 (Lusky and Botchan, Nature 293: 79-81, 981) vector sequences.)
  • Transfectants were selected in growth medium containing methotrexate.
  • ELISA enzyme-linked immunosorbant assay
  • chromophore 100 ⁇ l ABTS (2,2'-Azinobis(3-ethylbenz-thiazoline sulfonic acid diammonium salt; Sigma)+1 ⁇ l 30% H202+12.5 ml citrate/phosphate buffer (9.04 g/l citric acid, 10.16 g/l Na 2 HPO 4 )
  • citrate/phosphate buffer 9.04 g/l citric acid, 10.16 g/l Na 2 HPO 4
  • Spent media from drug resistant clones was also tested for the presence of secreted PDGF receptor analogs by immunoprecipitaiton.
  • Approximately one million drug resistant transfectants were grown in DMEM medium lacking cysteine+2% calf serum for 18 hours at 37° C. in the presence of 50 ⁇ CI 35 S-cysteine.
  • Media was harvested from the labeled cells and 250 ⁇ l of the spent media was assayed for binding to the anti-PDGF receptor antibody PR7212.
  • PR7212 diluted in PBS was added to the media to a final concentration of 2.5 ⁇ g per 250 ⁇ l spent media.
  • Five ⁇ l of rabbit anti-mouse Ig diluted in PBS was added to the PR7212/media mixtures.
  • the immunocomplexes were precipitated by the addition of 50 ⁇ l 110% fixed Staph A (weight/volume in PBS).
  • the immunocomplexes were analyzed on 8% SDS-polyacrylamide gels followed by autoradiography overnight at -70° C.
  • the results of the immunoprecipitation showed that the PDGF receptor anlaog secreted by the transfectants was bound by the anti-PDGF receptor antibody.
  • the combined results of the ELISA and immunoprecipitation assays showed that the PDGF receptor analog secreted by the transfectants contained both the PDGF receptor ligand-binding domain and the human light chain constant region.
  • Plasmid pSDL114 was cotransfected with p ⁇ 5V H huC.sub. ⁇ 71M-neo, which encodes a neomycin resistance gene expression unit and a complete mouse/human chimeric immunoglobulin heavy chain gene expression unit (10).
  • Plasmid p ⁇ 5V H huC.sub. ⁇ 1M-neo was constructed as follows.
  • the mouse immunoglobulin heavy chain gene was isolated from a lambda genomic DNA library constructed from the murine hybridoma cell line NR-ML-05 (Serafini et al., Eur. J. Nucl. Med. 14: 232, 1988) using an oligonucleotide probe designed to span the VH/D/JH junction (5' GCA TAG TAG TTA CCA TAT CCT CTT GCA CAG 3').
  • the human immunoglobulin gamma-1 C gene was isolated from a human genomic library using a cloned human gamma-4 constant region gene (Ellison et al., DNA 11-18, 1981).
  • the mouse immunoglobulin variable region was isolated as a 5.3 kb Sst I-Hind III fragment from the original phage clone and the human gamma-1 C gene was obtained from the original phage clone as a 6.0 kb Hind III-Xho I fragment.
  • the chimeric gamma-1 C gene was created by joining the V H and C H fragments via the common Hind III site and incorporating them with the E. coli neomycin resistance gene expression unit into pIC19H to yield p ⁇ 5V H huC.sub. ⁇ 1M-neo.
  • Plasmid pSDL114 was linearized by digestion with ClaI and was co-transfected into SP2/0-Ag14 cells with Asp718 linearized p ⁇ 5V H huC.sub. ⁇ 1M-neo. The transfectants were selected in growth medium containing methotrexate and neomycin. Media from drug-resistant clones were tested for their ability to bind PDGF in a competition binding assay.
  • the competition binding assay measured the amount of 125 I-PDGF left to bind to human dermal fibroblast cells after preincubation with the spent media from pSDL114-p ⁇ 5V H huC.sub. ⁇ 1M-neo transfected cells.
  • the media were serially diluted in binding medium (Table 4).
  • the dilutions were mixed with 0.5 ng of iodinated PDGF-BB or iodinated PDGF-AA and the mixtures were incubated for two hours at room temperature.
  • Three hundred ⁇ g of unlabeled PDGF-BB or unlabeled PDGF-AA was added to one tube from each series.
  • the sample mixtures were added to 24 well plates containing confluent human dermal fibroblast cells.
  • the cells were incubated with the mixture for four hours at 4° C.
  • the supernatants were aspirated from the wells, and the wells were rinsed three times with phosphate buffered saline that was held a 4° C. (PBS; Sigma, St. Louis, Mo.).
  • PBS phosphate buffered saline
  • Five hundred ⁇ l of PBS +1% NP-40 was added to each well, and the plates were shaken on a platform shaker for five minutes.
  • the cells were harvested and the amount of iodinated PDGF was determined.
  • the results of the competition binding assay showed that the protein produced from pSDL114-p ⁇ 5V H huC.sub. ⁇ 1M-neo transfected cells was able to competetively bind PDGF-BB but did not bind PDGF-AA.
  • the PDGF receptor analog produced from a pSDL114/p ⁇ 5V H huC.sub. ⁇ 1M-neo transfectant was assayed to determine if the receptor analog was able to bind PDGF-BB to saturation.
  • Eight and one half milliliters of spent media containing the PDGF-R analogs from a pSDL114/p ⁇ 5V H huC.sub. ⁇ 1M-neo transfectant was added to 425 ⁇ l of Sepharose Cl-4B-Protein A beads (Sigma), and the mixture was incubated for 10 minutes at 4° C. The beads were pelleted by centrifugation and washed with binding medium (Table 4).
  • Binding reactions were prepared by adding iodinated PDGF-BB diluted in DMEM+10% fetal calf serum to the identical aliquots of receptor-bound beads to final PDGF-BB concentrations of between 4.12 pM and 264 pM. Nonspecific binding was determined by adding a 100 fold excess of unlabeled BB to an identical set of binding reactions. Mixtures were incubated overnight at 4° C.
  • the beads were pelleted by centrifugation, and unbound receptor was removed with three washes in PBS. The beads were resuspended in 100 ⁇ l of PBS and were counted. Results of the assay showed that the PDGF-R analog was able to bind PDGF-BB with high affinity.
  • Plasmid pSDL110 was digested with Eco RI and Hind III to isolate the 1.65 kb PDGF-R fragment. Plasmid pICHu 65 -1M was used as the source of the heavy chain constant region and hinge region. Plasmid pICHu.sub. ⁇ -1M comprises the approximately 6 kb Hind III-Xho I fragment of a human gamma-1 C gene subcloned into pUC19 that had been linearized by digestion with Hind III and SaI I.
  • Plasmid pICHu.sub. ⁇ -1M was digested with Hind III and Eco RI to isolate the 6 kb fragment encoding the human heavy chain constant region. Plasmid pIC19H was linearized by digestion with Eco RI. The 1.65 kb PDGF-R fragment, the 6 kb heavy chain constant region fragment and the linearized pIC19H were joined in a three part ligation. The resultant plasmid, pSDLIII, was digested with Bam HI to isolate the 7.7 kb fragment. Plasmid p ⁇ PRE8 was linearized with Bgl II and was treated with calf intestinal phosphatase to prevent self-ligation. The 7.7 kb fragment and the linearized p ⁇ PRE8 were joined by ligation. A plasmid containing the insert in the proper orientation was designated pSDL113 (FIG. 8).
  • Plasmid pSDL113 is linearized by digestion with Cla I and was cotransfected with Pvu I-digested p416 into SP2/0-Ag14 by electroporation. Transfectants are selected in growth medium containing methotrexate.
  • Example 12.C Media from drug resistant clones are tested for the presence of secreted PDGF-R analogs by immunoprecipitation using the method described in Example 12.B. Competition binding assays (Example 12.C.) are carried out on media samples to determine ligand binding activity.
  • Plasmid pSDL113 is linearized by digestion with Cla I and is cotransfected with pIC ⁇ 5V.sub. ⁇ HuC.sub. ⁇ -Neo, which encodes a neomycin resistance gene and a mouse/human chimeric immunoglobulin light chain gene.
  • the mouse immunoglobulin light chain gene was isolated from a lambda genomic DNA library constructed from the murine hybridoma cell line NR-ML-05 (Woodhouse et al., ibid.) using an oligonucleotide probe designed to span the V.sub. ⁇ /J.sub. ⁇ junction (5' ACC GAA CGT GAG AGG AGT GCT ATA A 3').
  • the human immunoglobulin light chain constant region gene was isolated as described in Example 12.B.
  • the mouse NR-ML-05 immunoglobulin light chain variable region gene was subcloned from the original mouse genomic phage clone into pIC19R as a 3 kb Xba I-Hinc II fragment.
  • the human kappa C gene was subcloned from the original human genomic phage clone into pUC19 as a 2.0 kb Hind III-Eco RI fragment.
  • the chimeric kappa gene was created by joining the NR-ML-05 light chain variable region gene and human light chain constant region gene via the common Sph I site and incoporating them with the E. coli neomycin resistance gene into pIC19H to yield pIC ⁇ 5V.sub. ⁇ HuC.sub. ⁇ -Neo (FIG. 9).
  • the linearized pSDL113 and pIC ⁇ 5V.sub. ⁇ HuC.sub. ⁇ -Neo are transfected into SP2/0-Ag14 cells by electroporation.
  • the transfectants are selected in growth medium containing methotrexate and neomycin.
  • Media from drug-resistant clones are tested for their ability to bind PDGF in a competition binding assay.
  • a clone of SP2/0-Ag14 stably transfected with pSDL114 and p416 was co-transfected with Cla I-digested pSDL113 and Bam HI-digested pIC-neo by electroporation.
  • Plasmid pIC-neo comprises the SV40 promoter operatively linked to the E. coli neomycin resistance gene and pIC19H vector sequences.
  • Transfected cells were selected in growth medium containing methotrexate and G418. Media from drug-resistance clones were tested for their ability to bind PDGF in a competition binding assay as described in Example 12.C. The results of the assay showed that the transfectants secreted a PDGF receptor analog capable of competitively binding PDGF-BB.
  • Plasmid p ⁇ 5V H Fab-neo was constructed as follows.
  • Plasmid p24BRH (Ellison et al., DNA 1:11, 1988) was digested with Xma I and Eco RI to isolate the 0.2 kb fragment comprising the immunoglobulin 3' untranslated region.
  • Synthetic oligonucleotides ZC871 (Table 1) and ZC872 (Table 1) were kinased and annealed using essentially the methods described by Maniatis et al. (ibid.). The annealed oligonucleotides ZC871/ZC872 formed an Sst I-Xma I adapter.
  • the ZC871/ZC872 adapter, the 0.2 kb p24BRH fragment and Sst I-Eco RI linearized pUC19 were joined in a three-part ligation to form plasmid p ⁇ 4 3+.
  • Plasmid p ⁇ 4 3' was linearized by digestion with Bam HI and Hind III.
  • Plasmid p24BRH was cut with Hind III and Bgl II to isolate the 0.85 kb fragment comprising the C H 1 region.
  • the p ⁇ 4 3' fragment and the Hind III-Bgl II p24BRH fragment were joined by ligation to form plasmid p24Fab.
  • Plasmid p ⁇ 4 Fab was digested with Hind III and Eco RI to isolate the 1.2 kb fragment comprising ⁇ 4 Fab.
  • Plasmid pICneo comprising the SV40 promoter operatively linked to the neomycin resistance gene and pIC19H vector sequences, was linearized by digestion with Sst I and Eco RI.
  • Plasmid p ⁇ 5V H comprising the mouse immunoglobulin heavy chain gene variable region and pUC18 vector sequences, was digested with Sst I and Hind III to isolate the 5.3 kb V H fragment.
  • the linearized pICneo was joined with the 5.3 kb Sst I-Hind III fragment and the 1.2 kb Hind III-Eco RI fragment in a three-part ligation.
  • the resultant plasmid was designated p ⁇ 5V H Fab-neo (FIG. 10).
  • a pSDL114/p416-transfected SP2/0-AG14 clone was transfected with Sca I-linearized p ⁇ 5V H Fab-neo.
  • Transfected cells were selected in growth medium containing methotrexate and G418.
  • Media from drug-resistant clones were tested for their ability to bind PDGF in a competition binding assay as described in Example 12.C.
  • the results of the assay showed that the PDGF receptor analog secreted from the transfectants was capable of competitively binding PDGF-BB.
  • Plasmid pWKI was constructed as follows.
  • the immunoglobulin gamma-1 Fab' sequence comprising the C H 1 and hinge regions sequences, was derived from the gamma-1 gene clone described in Example 12.C.
  • the gamma-1 gene clone was digested with Hind III and Eco RI to isolate the 3.0 kb fragment, which was subcloned into Hind III-Eco RI linearized M13mp19.
  • Single-stranded template DNA from the resultant phage was subjected to site-directed mutagenesis using oligonucleotide ZC1447 (Table 1) and essentially the method of Zoller and Smith (ibid.).
  • a phage clone was identified having a ZC1447 induced deletion resulting in the fusion of the hinge region to a DNA sequence encoding the amino acids Ala-Leu-His-Asn-His-Tyr-Thr-Glu-Lys-Ser-Leu-Ser-Leu-Ser-Pro-Gly-Lys followed in-frame by a stop codon.
  • Replicative form DNA from a positive phage clone was digested with Hind III and Eco RI to isolate the 1.9 kb fragment comprising the C H I and hinge regions.
  • Plasmid p ⁇ 5V H was digested with Sst I and Hind III to isolate the 5.3 kb fragment comprising the mouse immunoglobulin heavy chain gene variable region.
  • Plasmid pICneo was linearized by digestion with Sst I and Eco RI. The linearized pICneo was joined with the 5.3 kb Hind III-Sst I fragment and the 1.9 kb Hind III-Eco RI fragment in a three-part ligation. The resultant plasmid was designated pWKI (FIG. 10).
  • Colonies of transformants were tested for secretion of PDGF receptor analogs by first growing the cells on nitrocellulose filters that had been laid on top of solid growth medium. Nitrocellulose filters (Schleicher & Schuell, Keene, N.H.) were placed on top of solid growth medium and were allowed to be completely wetted. Test colonies were patched onto the wetted filters and were grown at 30° C. for approximately 40 hours. The filters were then removed from the solid medium, and the cells were removed by four successive rinses with Western Transfer Buffer (Table 4). The nitrocellulose filters were soaked in Western Buffer A (Table 4) for one hour at room temperature on a shaking platform with two changes of buffer. Secreted PDGF-R analogs were visualized on the filters described below.
  • Nitrocellulose filters (Schleicher & Schuell, Keene, N.H.) were placed on top of solid growth medium and were allowed to be completely wetted. Test colonies were patched onto the wetted filters and were grown at 30° C. for approximately 40 hours. The filters
  • a nitrocellulose filter was soaked in Western Buffer A (Table 4) without the gelatin and placed in a Minifold (Schleicher & Schuell, Keene, N.H.). Five ml of culture supernatant was added without dilution to the Minifold wells, and the liquid was allowed to pass through the nitrocellulose filter by gravity. The nitrocellulose filter was removed from the minifold and was soaked in Western Buffer A (Table 3) for one hour on a shaking platform at room temperature. The buffer was changed three times during the hour incubation.
  • the transformants were analyzed by Western blot, essentially as described by Towbin et al. (Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979) and Gordon et al. (U.S. Pat. No. 4,452,901). Culture supernatants from appropriately grown transformants were diluted with three volumes of 95% ethanol. The ethanol mixtures were incubated overnight at -70° C. The precipitates were spun out of solution by centrifugation in an SS-24 rotor at 18,000 rpm for 20 minutes. The supernatants were discarded and the precipitate pellets were resuspended in 200 ⁇ l of dH 2 O. Two hundred ⁇ l of 2 ⁇ loading buffer (Table 4) was added to each sample, and the samples were incubated in a boiling water bath for 5 minutes.
  • the samples were electrophoresed in a 15% sodium dodecylsulfate polyacrylamide gel under non-reducing conditions.
  • the proteins were electrophoretically transferred to nitrocellulose paper using conditions described by Towbin et al. (ibid.).
  • the nitrocellulose filters were then incubated in Western Buffer A (Table 4) for 75 minutes at room temperature on a platform rocker.
  • Filters prepared as described above were screened for proteins capable of binding a PDGF receptor specific monoclonal antibody, designated PR7212.
  • the filters were removed from the Western Buffer A (Table 4) and placed in sealed plastic bags containing a 10 ml solution comprising 10 ⁇ g/ml PR7212 monoclonal antibody diluted in Western Buffer A.
  • the filters were incubated on a rocking platform overnight at 4° C. or for one hour at room temperature. Excess antibody was removed with three 15-minute washes with Western Buffer A on a shaking platform at room temperature.
  • the filters were pre-incubated for one hour at room temperature with a solution comprising 50 ⁇ l Vectastain Reagent A (Vector Laboratories) in 10 ml of Western Buffer A that had been allowed to incubate at room temperature for 30 minutes before use.
  • the filters were washed with one quick wash with distilled water followed by three 15-minute washes with Western Buffer B (Table 4) at room temperature.
  • the Western Buffer B washes were followed by one wash with distilled water.
  • the substrate reagent was prepared. Sixty mg of horseradish peroxidase reagent (Bio-Rad, Richmond, Calif.) was dissolved in 20 ml HPLC grade methanol. Ninety ml of distilled water was added to the dissolved peroxidase followed by 2.5 ml 2M Tris, pH 7.4 and 3.8 ml 4M NaCl. 100 ⁇ l of 30% H 2 O was added just before use. The washed filters were incubated with 75 ml of substrate and incubated at room temperature for 10 minutes with vigorous shaking. After the 10 minute incubation, the buffer was changed, and the filters were incubated for an additional 10 minutes. The filters were then washed in distilled water for one hour at room temperature. Positives were scored as those samples which exhibited coloration.
  • Filters prepared as described above were probed with an anti-substance P antibody.
  • the filters were removed from the Western Buffer A and rinsed with Western transfer buffer, followed by a 5-minute wash in phosphate buffered saline (PBS, Sigma, St. Louis, Mo.).
  • PBS phosphate buffered saline
  • the filters were incubated with a 10 ml solution containing 0.5M 1-ethyl-3-3-dimethylamino propyl carbodiimide (Sigma) in 1.0M NH 4 Cl for 40 minutes at room temperature. After incubation, the filters were washed three times, for 5 minutes per wash, in PBS. The filters were blocked with 2% powdered milk diluted in PBS.
  • the filters were then incubated with a rat anti-substance P monoclonal antibody (Accurate Chemical & Scientific Corp., Westbury, N.Y.). Ten ⁇ l of the antibody was diluted in 10 ml of antibody solution (PBS containing 20% fetal calf serum and 0.5% Tween-20). The filters were incubated at room temperature for 1 hour. Unbound antibody was removed with four 5-minute washes with PBS.
  • the filters were then incubated with a biotin-conjugated rabbit anti-rat peroxidase antibody (Cappel Laboratories, Melvern, Pa.).
  • the conjugated antibody was diluted 1:1000 in 10 ml of antibody solution for 2 hours at room temperature. Excess conjugated antibody was removed with four 5-minute washes with PBS.
  • the filters were pre-incubated for 30 minutes at room temperature with a solution containing 50 ⁇ l Vectastain Reagent A (Vector Laboratories) and 50 ⁇ l Vectastain Reagent B (Vector Laboratories) in 10 ml of antibody solution that had been allowed to incubate for 30 minutes before use. Excess Vectastain reagents were removed by four 5-minute washes with PBS.
  • the substrate reagent was prepared. 60 mg of horseradish peroxidase reagent (Bio-Rad) was dissolved in 25 ml of HPLC grade methanol. Approximately 100 ml of PBS and 200 ⁇ l H 2 O 2 were added just before use. The filters were incubated with the substrate reagent for 10 to 20 minutes. The substrate was removed by a vigorous washing distilled water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
US07/347,291 1988-01-22 1989-05-02 Method of producing secreted receptor analogs and biologically active peptide dimers Expired - Lifetime US5155027A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US08/180,195 US5567584A (en) 1988-01-22 1994-01-11 Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US08/475,458 US5843725A (en) 1988-01-22 1995-06-07 Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US08/477,329 US5750375A (en) 1988-01-22 1995-06-07 Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US08/980,400 US6018026A (en) 1988-01-22 1997-11-26 Biologically active dimerized and multimerized polypeptide fusions
US09/435,059 US6323323B1 (en) 1988-01-22 1999-10-25 Ligand-binding, dimerized polypeptide fusions
US09/583,449 US6300099B1 (en) 1988-01-22 2000-05-30 Methods for producing secreted ligand-binding fusion proteins
US09/583,210 US6291646B1 (en) 1988-01-22 2000-05-30 Dimerized polypeptide fusions
US09/583,459 US6291212B1 (en) 1988-01-22 2000-05-30 DNA constructs encoding ligand-binding fusion proteins
US09/955,363 US20020173621A1 (en) 1988-01-22 2001-09-18 Method for producing dimerized polypeptide fusions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14687788A 1988-01-22 1988-01-22
EP89100787.4 1989-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14687788A Continuation-In-Part 1988-01-22 1988-01-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US63451090A Continuation-In-Part 1988-01-22 1990-12-27

Publications (1)

Publication Number Publication Date
US5155027A true US5155027A (en) 1992-10-13

Family

ID=22519371

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/347,291 Expired - Lifetime US5155027A (en) 1988-01-22 1989-05-02 Method of producing secreted receptor analogs and biologically active peptide dimers

Country Status (11)

Country Link
US (1) US5155027A (de)
EP (3) EP0721983A1 (de)
JP (1) JP3424823B2 (de)
AT (1) ATE140963T1 (de)
AU (1) AU628035B2 (de)
CA (1) CA1340908C (de)
DE (2) DE68926888T2 (de)
DK (1) DK175949B1 (de)
ES (1) ES2092468T3 (de)
GR (1) GR3021102T3 (de)
IE (1) IE80960B1 (de)

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010151A1 (en) * 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
WO1993011223A1 (en) * 1991-12-02 1993-06-10 Cor Therapeutics, Inc. Methods for production of purified soluble type b and type a human platelet-derived growth factor receptor fragments
US5420247A (en) * 1990-12-13 1995-05-30 Immunex Corporation Leukemia inhibitory factor receptors and fusion proteins
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
US5554499A (en) * 1990-10-05 1996-09-10 President And Fellows Of Harvard College Detection and isolation of ligands
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5686572A (en) * 1991-01-31 1997-11-11 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5843725A (en) * 1988-01-22 1998-12-01 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
USRE36755E (en) * 1989-09-05 2000-06-27 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
US6193972B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone
US6201105B1 (en) 1989-09-05 2001-03-13 Craig A. Smith Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US20030049798A1 (en) * 1998-03-17 2003-03-13 Laura Carter MU-1, member of the cytokine receptor family
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US20030108549A1 (en) * 1998-03-17 2003-06-12 Wyeth Methods and compositions for modulating interleukin-21 receptor activity
WO2003089603A2 (en) 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US20040001853A1 (en) * 2002-06-20 2004-01-01 Rajan George Chimeric antigens for eliciting an immune response
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
US20040136954A1 (en) * 2002-07-15 2004-07-15 Grusby Michael J. Methods and compositions for modulating T helper (Th) cell development and function
US20040191253A1 (en) * 1993-02-25 2004-09-30 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US20040265321A1 (en) * 2003-01-13 2004-12-30 Johnson Leslie S Soluble FcgammaR fusion protiens and methods of use thereof
US20050003424A1 (en) * 1996-03-13 2005-01-06 Baumgartner James W. Testis-specific receptor
US20050013828A1 (en) * 2002-06-20 2005-01-20 Virexx Medical Corp. Chimeric antigens for eliciting an immune response
US20050186662A1 (en) * 2004-01-28 2005-08-25 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
WO2005087810A2 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US20060051844A1 (en) * 2004-09-03 2006-03-09 Heavner George A Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060275868A1 (en) * 1989-09-05 2006-12-07 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US20070071760A1 (en) * 2005-08-09 2007-03-29 Herve Broly Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US20070098683A1 (en) * 1999-03-09 2007-05-03 Zymogenetics, Inc. Cytokine zalpha11 ligand antibodies
US20070148715A1 (en) * 2003-08-14 2007-06-28 Lalev Atanas I Method for detecting transient ligand interactions
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
US20070274984A1 (en) * 2006-05-15 2007-11-29 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
US20080075696A1 (en) * 2004-12-16 2008-03-27 Ian Parsons Treatment Of Hepatitis C In The Asian Population With Interferon-Beta
US20080167241A1 (en) * 1998-03-17 2008-07-10 Genetics Institute, Llc Mu-1, member of the cytokine receptor family
US20080226662A1 (en) * 2000-04-28 2008-09-18 The Johns Hopkins University Dendritic cell co-stimulatory molecules
EP1988102A1 (de) 1998-12-07 2008-11-05 ZymoGenetics, Inc. Wachstumsfaktor homolog ZVEGF3
US20080317711A1 (en) * 2005-09-01 2008-12-25 Robert Sergott Treatment of Optic Neuritis
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
EP2087905A2 (de) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 zur Behandlung und Diagnose von mit Neovaskularization verbunden Zuständen
US20090221481A1 (en) * 2005-07-28 2009-09-03 Vittorio Enrico Avvedimento Stimulatory auto-antibodies to the pdgf receptors as pathology marker and therapeutic target
US20090226416A1 (en) * 2001-02-09 2009-09-10 Human Genome Sciences, Inc. Human G-Protein Chemokine Receptor (CCR5) HDGNR10
EP2100619A1 (de) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
EP2105446A2 (de) 1998-09-23 2009-09-30 ZymoGenetics, Inc. Zytokinrezeptor Zalpha11
US20090258031A1 (en) * 2007-11-01 2009-10-15 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
EP2128174A1 (de) 1999-12-09 2009-12-02 Richard S. Kornbluth Multimere Formen von TNF-Superfamilienliganden
EP2130919A1 (de) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21-Antagonisten
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
EP2192132A2 (de) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
EP2194130A1 (de) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Zytokin ZCYT018
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
US20100230448A1 (en) * 2007-05-17 2010-09-16 Julianne Desautels Spout for food stuff container
EP2230299A1 (de) 2002-01-18 2010-09-22 ZymoGenetics, Inc. Neuartiger Zytokin-ZCYTOR17-Ligand
EP2258725A2 (de) 2000-06-26 2010-12-08 ZymoGenetics, L.L.C. Cytokinrezeptor zcytor17
EP2263684A1 (de) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 Derivate
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
EP2289525A1 (de) 2002-06-07 2011-03-02 ZymoGenetics, Inc. Verwendung von IL-21 zur Vermehrung von Lymhoidzellen, und für adoptive Immuntherapie gegen Krebs
EP2295577A2 (de) 1999-03-09 2011-03-16 ZymoGenetics, Inc. Menschliche Zytokine als Liganden des Z-Alpha-Rezeptors und Verwendungen davon
EP2338910A1 (de) 2002-01-18 2011-06-29 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20110223185A1 (en) * 2005-10-13 2011-09-15 Rajan George Chimeric hepatitis c virus antigens for eliciting an immune response
US8039589B1 (en) 2002-10-04 2011-10-18 Mayo Foundation For Medical Education And Research B7-DC variants
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
WO2011156356A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
EP2397493A1 (de) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Modulation von Immunantworten
EP2425847A1 (de) 2004-05-20 2012-03-07 ZymoGenetics, Inc. Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper
EP2511299A1 (de) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanisierte, anti-CD70-bindende Wirkstoffe und ihre Verwendung
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
EP2567973A2 (de) 2005-11-28 2013-03-13 Zymogenetics, Inc. IL-21-Antagonisten
US8460927B2 (en) 1999-11-30 2013-06-11 Mayo Foundation For Medical Education And Research B7-H1 antibodies and method of use
EP2609932A2 (de) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Veränderliche Target-Bindemittel und Verwendungen davon
EP2623112A1 (de) 2008-06-27 2013-08-07 Zymogenetics, Inc. Lösliche hybride FC-Gamma-Rezeptoren und zugehörige Verfahren
EP2633866A2 (de) 2003-10-17 2013-09-04 Novo Nordisk A/S Kombinationstherapie
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2014079384A1 (zh) 2012-11-22 2014-05-30 苏州康宁杰瑞生物科技有限公司 促激素融合蛋白及其制备方法和用途
US8747833B2 (en) 2004-10-06 2014-06-10 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9441029B2 (en) 2010-08-06 2016-09-13 Genzyme Corporation VEGF antagonist compositions and uses thereof
US9724390B2 (en) 2015-02-03 2017-08-08 Oncomed Pharmaceuticals, Inc. Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents
US10167336B2 (en) 2013-03-14 2019-01-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
WO2021138264A1 (en) 2019-12-30 2021-07-08 Seagen Inc. Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US6110737A (en) 1988-02-02 2000-08-29 The Regents Of The University Of California Human platelet-derived growth factor receptor, type A
US6372438B1 (en) 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
JP2892726B2 (ja) * 1988-06-30 1999-05-17 コア セラピューティクス，インコーポレイティド 血小板阻止ペプチド
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
IL95641A0 (en) * 1989-09-15 1991-06-30 Curative Tech Inc Preparation of a platelet releasate product
JP2009165489A (ja) * 1989-11-22 2009-07-30 Genentech Inc リガンド結合タンパク質および安定血漿タンパク質からなる融合タンパク質
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CA2146559A1 (en) * 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
ZA942206B (en) * 1993-04-01 1994-10-31 Amgen Inc Biologically active polypeptide fusion dimers
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
CA2182498A1 (en) 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
US5955300A (en) 1994-05-06 1999-09-21 Institut Gustave Roussy Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2274315A1 (en) * 1996-12-06 1998-06-11 Niels Pallisgaard Detection of chromosomal abnormalities
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
FR2781149B1 (fr) * 1998-07-17 2001-09-07 Oreal Composition deodorante contenant un sel d'alun
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
DK1119371T3 (da) 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
ES2388341T3 (es) 1998-10-23 2012-10-11 Kirin-Amgen Inc. Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MPL y que tienen actividad trombopoyética
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
EP1446478B1 (de) * 2001-10-19 2008-01-23 ZymoGenetics, Inc. Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
US20030175745A1 (en) * 2001-11-28 2003-09-18 Dean Cheryl H. Peptides with growth inhibitory action
WO2005038465A2 (en) * 2003-10-07 2005-04-28 Centelion Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
JP5017116B2 (ja) 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド 修飾Ｆｃ分子
CA2583027A1 (en) 2004-11-02 2006-10-19 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB120694A (en) * 1918-03-21 1918-11-21 Horace Turner Brereton A New or Improved Aeroplane Inclinometer.
EP0116201A1 (de) * 1983-01-12 1984-08-22 Chiron Corporation Sekretorische Expression in Eukaryoten
EP0162319A2 (de) * 1984-04-24 1985-11-27 Tasuku Honjo Verfahren zur Ligation von heterogenen Genen
EP0173494A2 (de) * 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
WO1986001533A1 (en) * 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0239400A2 (de) * 1986-03-27 1987-09-30 Medical Research Council Rekombinante Antikörper und Verfahren zu deren Herstellung
EP0256654A2 (de) * 1986-07-07 1988-02-24 Centocor, Inc. Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4816397A (en) * 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
EP0315062A2 (de) * 1987-10-27 1989-05-10 Bristol-Myers Squibb Company Herstellung von schimären Antikörpern durch homologe Rekombination
EP0088994B1 (de) * 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
EP0171496B1 (de) * 1984-08-15 1993-05-26 Research Development Corporation of Japan Verfahren zur Herstellung von chimärischen monoklonalen Antikörpern

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
AU607306B2 (en) * 1988-02-02 1991-02-28 Regents Of The University Of California, The Human platelet-derived growth factor receptor

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB120694A (en) * 1918-03-21 1918-11-21 Horace Turner Brereton A New or Improved Aeroplane Inclinometer.
EP0088994B1 (de) * 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
EP0116201A1 (de) * 1983-01-12 1984-08-22 Chiron Corporation Sekretorische Expression in Eukaryoten
US4816397A (en) * 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
EP0162319A2 (de) * 1984-04-24 1985-11-27 Tasuku Honjo Verfahren zur Ligation von heterogenen Genen
EP0171496B1 (de) * 1984-08-15 1993-05-26 Research Development Corporation of Japan Verfahren zur Herstellung von chimärischen monoklonalen Antikörpern
EP0173494A2 (de) * 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
WO1986001533A1 (en) * 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0239400A2 (de) * 1986-03-27 1987-09-30 Medical Research Council Rekombinante Antikörper und Verfahren zu deren Herstellung
EP0256654A2 (de) * 1986-07-07 1988-02-24 Centocor, Inc. Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
EP0315062A2 (de) * 1987-10-27 1989-05-10 Bristol-Myers Squibb Company Herstellung von schimären Antikörpern durch homologe Rekombination

Non-Patent Citations (84)

* Cited by examiner, † Cited by third party
Title
Alber and Kawasaki, J. Mol. Appl. Genet. 1: 419 434, 1982. *
Alber and Kawasaki, J. Mol. Appl. Genet. 1: 419-434, 1982.
Bailon et al. Bio/Technology 5: 1195 1198, 1987. *
Bailon et al. Bio/Technology 5: 1195-1198, 1987.
Ballou et al., J. Biol. Chem. 255: 5986 5991, 1980. *
Ballou et al., J. Biol. Chem. 255: 5986-5991, 1980.
Beggs, Nature: 104 108, 1978. *
Beggs, Nature: 104-108, 1978.
Boni Schnetzler and Pilch, Proc. Natl. Acad. Sci. USA 84: 7832 7836, 1987. *
Boni-Schnetzler and Pilch, Proc. Natl. Acad. Sci. USA 84: 7832-7836, 1987.
Broach et al., Gene 8: 121 133, 1979. *
Broach et al., Gene 8: 121-133, 1979.
Capon et al., Nature 337: 525 531, 1989. *
Capon et al., Nature 337: 525-531, 1989.
Carlson et al., Mol. Cell. Biol. 3: 439 447, 1983. *
Carlson et al., Mol. Cell. Biol. 3: 439-447, 1983.
Claesson Welsh et al., Mol. Cell. Biol. 8: 3476 3486, 1988. *
Claesson-Welsh et al., Mol. Cell. Biol. 8: 3476-3486, 1988.
Clarke et al., Meth. Enzym. 68: 436 442, 1979. *
Clarke et al., Meth. Enzym. 68: 436-442, 1979.
Derynck et al., Nature 316: 701 705, 1985. *
Derynck et al., Nature 316: 701-705, 1985.
Ebina et al., Cell 40: 747 758, 1985. *
Ebina et al., Cell 40: 747-758, 1985.
Escobedo et al., Science 240: 1532 1534, 1988. *
Escobedo et al., Science 240: 1532-1534, 1988.
Gascoigne et al., Proc. Natl. Acad. Sci USA 84: 2936 2940, 1987. *
Gascoigne et al., Proc. Natl. Acad. Sci USA 84: 2936-2940, 1987.
Grosschedl and Baltimore, Cell 41: 885 897, 1985. *
Grosschedl and Baltimore, Cell 41: 885-897, 1985.
Hart et al., Science 240: 1529 1531, 1988. *
Hart et al., Science 240: 1529-1531, 1988.
Heldin et al., EMBO J. 7: 1387 1393, 1988. *
Heldin et al., EMBO J. 7: 1387-1393, 1988.
Hieter et al., Cell 22: 197 207, 1980. *
Hieter et al., Cell 22: 197-207, 1980.
Honjo et al., Cell 18: 559 568, 1979. *
Honjo et al., Cell 18: 559-568, 1979.
Livneh et al., J. Biol. Chem. 261: 12490 12497, 1986. *
Livneh et al., J. Biol. Chem. 261: 12490-12497, 1986.
Loh et al., Cell 33: 85 93, 1983. *
Loh et al., Cell 33: 85-93, 1983.
Maddon et al., Cell 42: 93 104, 1985. *
Maddon et al., Cell 42: 93-104, 1985.
Maddon et al., Cell 47: 333 348, 1986. *
Maddon et al., Cell 47: 333-348, 1986.
Marx, Science, 229: 455 456, 1985. *
Marx, Science, 229: 455-456, 1985.
Munro and Pelham, EMBO J. 3: 3087 3093, 1984. *
Munro and Pelham, EMBO J. 3: 3087-3093, 1984.
Neuberger et al., Nature 312: 604 609, 1984. *
Neuberger et al., Nature 312: 604-609, 1984.
Oi and Morrison, Biotechniques 4: 214 221, 1986. *
Oi and Morrison, Biotechniques 4: 214-221, 1986.
Radeke et al., Nature 325: 593 597, 1987. *
Radeke et al., Nature 325: 593-597, 1987.
Riedel et al., Nature 324: 68 70, 1986. *
Riedel et al., Nature 324: 68-70, 1986.
Riedel et al., Science 236: 197 200, 1987. *
Riedel et al., Science 236: 197-200, 1987.
Roth et al., J. Cell. Biol. 102: 1271 1283, 1986. *
Roth et al., J. Cell. Biol. 102: 1271-1283, 1986.
Rubin et al., J. Immun. 135: 3172 3177, 1985. *
Rubin et al., J. Immun. 135: 3172-3177, 1985.
Russell et al., Nature 304: 652 654, 1983. *
Russell et al., Nature 304: 652-654, 1983.
Smith et al., Science 238: 1704 1707, 1987. *
Smith et al., Science 238: 1704-1707, 1987.
Struhl et al., Proc. Natl. Acad. Sci. USA 76: 1035 1039, 1979. *
Struhl et al., Proc. Natl. Acad. Sci. USA 76: 1035-1039, 1979.
Treiger et al., J. Immunol. 136: 4099 4105, 1986. *
Treiger et al., J. Immunol. 136: 4099-4105, 1986.
Ullrich et al., Nature 309:418 425, 1984. *
Ullrich et al., Nature 309:418-425, 1984.
Ullrich et al., Nature 313: 756 761, 1985. *
Ullrich et al., Nature 313: 756-761, 1985.
von Heijne, Eur. J. Biochem. 133: 17 21, 1983. *
von Heijne, Eur. J. Biochem. 133: 17-21, 1983.
von Heijne, Nuc. Acids. Res. 14: 4683 4690, 1986. *
von Heijne, Nuc. Acids. Res. 14: 4683-4690, 1986.
Wood et al., Nature 314: 446 449, 1985. *
Wood et al., Nature 314: 446-449, 1985.
Yarden et al., Nature 323: 226 232, 1986. *
Yarden et al., Nature 323: 226-232, 1986.

Cited By (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5843725A (en) * 1988-01-22 1998-12-01 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6291212B1 (en) * 1988-01-22 2001-09-18 Zymogenetics, Inc. DNA constructs encoding ligand-binding fusion proteins
US6300099B1 (en) * 1988-01-22 2001-10-09 Zymogenetics, Inc. Methods for producing secreted ligand-binding fusion proteins
US6323323B1 (en) 1988-01-22 2001-11-27 Zymogenetics, Inc. Ligand-binding, dimerized polypeptide fusions
US7459528B2 (en) 1989-09-05 2008-12-02 Immunex Corporation Glycoproteins which bind to TNF
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6572852B2 (en) 1989-09-05 2003-06-03 Immunex Corporation Method for suppressing inflammatory responses by administering TNFR
US20030082736A1 (en) * 1989-09-05 2003-05-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
USRE36755E (en) * 1989-09-05 2000-06-27 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6201105B1 (en) 1989-09-05 2001-03-13 Craig A. Smith Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
US20030165459A1 (en) * 1989-09-05 2003-09-04 Immunex Corporation Antibodies which specifically bind to TNF-R
US20060067934A1 (en) * 1989-09-05 2006-03-30 Immunex Corporation Glycoproteins which bind to TNF
US7057022B2 (en) 1989-09-05 2006-06-06 Immunex Corporation Antibodies which specifically bind to TNF-R
US20060275868A1 (en) * 1989-09-05 2006-12-07 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
US8163522B1 (en) 1989-09-12 2012-04-24 Hoffman-Laroche Inc. Human TNF receptor
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5869618A (en) * 1990-05-25 1999-02-09 Lippman; Marc E. Antibodies to ligand growth factors
US6040290A (en) * 1990-05-25 2000-03-21 Georgetown University Ligand growth factor gp30 that binds to the erbB-2 receptor protein and induces cellular responses
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US5554499A (en) * 1990-10-05 1996-09-10 President And Fellows Of Harvard College Detection and isolation of ligands
US5801000A (en) * 1990-10-05 1998-09-01 President And Fellows Of Harvard College Detection and isolation of receptors
US5785967A (en) * 1990-12-13 1998-07-28 Immunex Corporation Antibodies immunoreactive with leukemia inhibitory factor receptors
US5420247A (en) * 1990-12-13 1995-05-30 Immunex Corporation Leukemia inhibitory factor receptors and fusion proteins
US5891652A (en) * 1991-01-31 1999-04-06 The Regents Of The University Of California Methods of using domains of extracellular region of human platelet-derived growth factor receptor polypeptides
US5686572A (en) * 1991-01-31 1997-11-11 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993010151A1 (en) * 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
US5426048A (en) * 1991-11-22 1995-06-20 Immunex Corporation DNA encoding a fusion receptor for oncostatin M and leukemia inhibitory factor
WO1993011223A1 (en) * 1991-12-02 1993-06-10 Cor Therapeutics, Inc. Methods for production of purified soluble type b and type a human platelet-derived growth factor receptor fragments
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US20040191253A1 (en) * 1993-02-25 2004-09-30 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6193972B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone
US20090240039A1 (en) * 1996-02-20 2009-09-24 Laboratoires Serono Sa Polypeptide fusion
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
US20100075402A1 (en) * 1996-02-20 2010-03-25 Laboratoires Serono Sa DNA coding for polypeptide fusion
US7291339B2 (en) 1996-02-20 2007-11-06 Laboratoires Serono Sa Homogeneity and secretion of a recombinant follicle stimulating hormone (FSH) in mammalian systems
US6663867B2 (en) 1996-02-20 2003-12-16 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone comprising a TNF binding protein and a glycoprotein hormone subunit and method of using same
US20040230034A1 (en) * 1996-02-20 2004-11-18 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone and method of using same
US20050020824A1 (en) * 1996-03-13 2005-01-27 Baumgartner James W. Testis-specific receptor
US20050003424A1 (en) * 1996-03-13 2005-01-06 Baumgartner James W. Testis-specific receptor
US5925735A (en) * 1996-05-23 1999-07-20 Zymogenetics, Inc. Hematopoietic cytokine receptor
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20030049798A1 (en) * 1998-03-17 2003-03-13 Laura Carter MU-1, member of the cytokine receptor family
US20080167241A1 (en) * 1998-03-17 2008-07-10 Genetics Institute, Llc Mu-1, member of the cytokine receptor family
US7705123B2 (en) 1998-03-17 2010-04-27 Genetics Institute, Llc MU-1, member of the cytokine receptor family
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7994292B2 (en) 1998-03-17 2011-08-09 Genetics Institute, Llc MU-1, member of the cytokine receptor family
US20030108549A1 (en) * 1998-03-17 2003-06-12 Wyeth Methods and compositions for modulating interleukin-21 receptor activity
EP2105446A2 (de) 1998-09-23 2009-09-30 ZymoGenetics, Inc. Zytokinrezeptor Zalpha11
EP1988102A1 (de) 1998-12-07 2008-11-05 ZymoGenetics, Inc. Wachstumsfaktor homolog ZVEGF3
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6806261B2 (en) 1998-12-31 2004-10-19 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
EP2256199A1 (de) 1999-01-07 2010-12-01 ZymoGenetics, Inc. Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US20040063910A1 (en) * 1999-02-08 2004-04-01 Chiron Corporation Fibroblast growth factor
EP2295577A2 (de) 1999-03-09 2011-03-16 ZymoGenetics, Inc. Menschliche Zytokine als Liganden des Z-Alpha-Rezeptors und Verwendungen davon
US20070098683A1 (en) * 1999-03-09 2007-05-03 Zymogenetics, Inc. Cytokine zalpha11 ligand antibodies
US20100297063A1 (en) * 1999-03-09 2010-11-25 Zymogenetics, Inc. Cytokine zalpha11 ligand antibodies
US8460927B2 (en) 1999-11-30 2013-06-11 Mayo Foundation For Medical Education And Research B7-H1 antibodies and method of use
EP2128174A1 (de) 1999-12-09 2009-12-02 Richard S. Kornbluth Multimere Formen von TNF-Superfamilienliganden
EP2194130A1 (de) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Zytokin ZCYT018
US20080241175A1 (en) * 2000-04-28 2008-10-02 The Johns Hopkins University Dendritic Cell Co-Stimulatory Molecules
US20080226662A1 (en) * 2000-04-28 2008-09-18 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8053558B2 (en) 2000-04-28 2011-11-08 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8053414B2 (en) 2000-04-28 2011-11-08 The Johns Hopkins University Methods of using B7-DC molecules to induce or enhance an immune response
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
EP2258725A2 (de) 2000-06-26 2010-12-08 ZymoGenetics, L.L.C. Cytokinrezeptor zcytor17
US20090226416A1 (en) * 2001-02-09 2009-09-10 Human Genome Sciences, Inc. Human G-Protein Chemokine Receptor (CCR5) HDGNR10
US20110081360A1 (en) * 2001-02-09 2011-04-07 Human Genome Sciences, Inc. Human G-Protein Chemokine Receptor (CCR5) HDGNR10
US7862818B2 (en) 2001-02-09 2011-01-04 Human Genome Sciences, Inc. Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10
EP2130919A1 (de) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21-Antagonisten
EP2840089A1 (de) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
EP2230299A1 (de) 2002-01-18 2010-09-22 ZymoGenetics, Inc. Neuartiger Zytokin-ZCYTOR17-Ligand
EP2338910A1 (de) 2002-01-18 2011-06-29 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
WO2003089603A2 (en) 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
EP2295455A1 (de) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokinrezeptor
EP2380633A1 (de) 2002-06-07 2011-10-26 ZymoGenetics, Inc. Verwendung von IL-21 bei Krebs
EP2377547A1 (de) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Verwendung von IL-21als antimikrobiellen Mittel
EP2289525A1 (de) 2002-06-07 2011-03-02 ZymoGenetics, Inc. Verwendung von IL-21 zur Vermehrung von Lymhoidzellen, und für adoptive Immuntherapie gegen Krebs
EP2377549A1 (de) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Verwendung von IL-21 zur Behandlung von Virusinfektionen
US8465745B2 (en) 2002-06-20 2013-06-18 Akshaya Bio Inc. Chimeric antigens for eliciting an immune response
US20040001853A1 (en) * 2002-06-20 2004-01-01 Rajan George Chimeric antigens for eliciting an immune response
US20050013828A1 (en) * 2002-06-20 2005-01-20 Virexx Medical Corp. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7314623B2 (en) 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
US7731946B2 (en) 2002-07-15 2010-06-08 Wyeth Llc Methods and compositions for modulating T helper (TH) cell development and function
US20040136954A1 (en) * 2002-07-15 2004-07-15 Grusby Michael J. Methods and compositions for modulating T helper (Th) cell development and function
US8039589B1 (en) 2002-10-04 2011-10-18 Mayo Foundation For Medical Education And Research B7-DC variants
US8273864B2 (en) 2002-10-04 2012-09-25 Mayo Foundation For Medical Education And Research Nucleic acid molecules encoding B7-DC variants
US7700100B2 (en) 2003-01-13 2010-04-20 Macrogenics, Inc. FcγRIIB fusion proteins and compositions thereof
US20100196372A1 (en) * 2003-01-13 2010-08-05 Macrogenics, Inc. FcgammaRIIB Fusion Proteins and Compositions Thereof
US20040265321A1 (en) * 2003-01-13 2004-12-30 Johnson Leslie S Soluble FcgammaR fusion protiens and methods of use thereof
EP2289559A1 (de) 2003-02-20 2011-03-02 Seattle Genetics, Inc. Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
EP2100619A1 (de) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
EP2087905A2 (de) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 zur Behandlung und Diagnose von mit Neovaskularization verbunden Zuständen
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20070148715A1 (en) * 2003-08-14 2007-06-28 Lalev Atanas I Method for detecting transient ligand interactions
EP2263684A1 (de) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 Derivate
EP2641611A2 (de) 2003-10-17 2013-09-25 Novo Nordisk A/S Kombinationstherapie
EP2633866A2 (de) 2003-10-17 2013-09-04 Novo Nordisk A/S Kombinationstherapie
US20100291079A1 (en) * 2004-01-28 2010-11-18 Low Susan C Heterodimeric Follicle Stimulating Hormone-Fc (FSH-Fc) Fusion Proteins for the Treatment of Infertility
US20050186662A1 (en) * 2004-01-28 2005-08-25 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US7601516B2 (en) 2004-01-28 2009-10-13 Syntomix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US8293707B2 (en) 2004-01-28 2012-10-23 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for increasing FSH activity
WO2005087810A2 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
EP2431050A1 (de) 2004-05-20 2012-03-21 ZymoGenetics, L.L.C. Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper
EP2425847A1 (de) 2004-05-20 2012-03-07 ZymoGenetics, Inc. Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper
EP2428216A2 (de) 2004-05-20 2012-03-14 ZymoGenetics, Inc. Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper
US7718176B2 (en) 2004-09-03 2010-05-18 Cna Development Llc Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060051844A1 (en) * 2004-09-03 2006-03-09 Heavner George A Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20100249032A1 (en) * 2004-09-03 2010-09-30 Heavner George A Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses
US9815892B2 (en) 2004-09-13 2017-11-14 Genzyme Corporation Multimeric constructs
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs
US7928072B2 (en) 2004-09-13 2011-04-19 Genzyme Corporation Multimeric constructs
US8658602B2 (en) 2004-09-13 2014-02-25 GenzymeCorporation Multimeric constructs
US11242387B2 (en) 2004-10-06 2022-02-08 Mayo Foundation For Medical Education And Research Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US8747833B2 (en) 2004-10-06 2014-06-10 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
US11939378B2 (en) 2004-10-06 2024-03-26 Mayo Foundation For Medical Education And Research Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US9803015B2 (en) 2004-10-06 2017-10-31 Mayo Foundation For Medical Education And Research Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US20080075696A1 (en) * 2004-12-16 2008-03-27 Ian Parsons Treatment Of Hepatitis C In The Asian Population With Interferon-Beta
EP2192132A2 (de) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
EP2511299A1 (de) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanisierte, anti-CD70-bindende Wirkstoffe und ihre Verwendung
EP2399932A1 (de) 2005-05-12 2011-12-28 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Modulation von Immunantworten
EP3683230A1 (de) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
EP2397493A1 (de) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Modulation von Immunantworten
EP3214095A1 (de) 2005-05-12 2017-09-06 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
US20090221481A1 (en) * 2005-07-28 2009-09-03 Vittorio Enrico Avvedimento Stimulatory auto-antibodies to the pdgf receptors as pathology marker and therapeutic target
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US20070071760A1 (en) * 2005-08-09 2007-03-29 Herve Broly Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US8178083B2 (en) 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
US20080317711A1 (en) * 2005-09-01 2008-12-25 Robert Sergott Treatment of Optic Neuritis
US20110223185A1 (en) * 2005-10-13 2011-09-15 Rajan George Chimeric hepatitis c virus antigens for eliciting an immune response
EP2567973A2 (de) 2005-11-28 2013-03-13 Zymogenetics, Inc. IL-21-Antagonisten
EP2805971A1 (de) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21-Antagonisten
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US20070274984A1 (en) * 2006-05-15 2007-11-29 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US10555913B2 (en) 2006-05-24 2020-02-11 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2609932A2 (de) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Veränderliche Target-Bindemittel und Verwendungen davon
US20100230448A1 (en) * 2007-05-17 2010-09-16 Julianne Desautels Spout for food stuff container
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
US8445447B2 (en) 2007-07-13 2013-05-21 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
US20110130546A1 (en) * 2007-11-01 2011-06-02 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8268587B2 (en) 2007-11-01 2012-09-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US7794718B2 (en) 2007-11-01 2010-09-14 Perseid Therapeutics, LLC Immunosuppressive polypeptides and nucleic acids
US8496935B2 (en) 2007-11-01 2013-07-30 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8491899B2 (en) 2007-11-01 2013-07-23 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20100260759A1 (en) * 2007-11-01 2010-10-14 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20090258031A1 (en) * 2007-11-01 2009-10-15 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
US8445230B2 (en) 2007-11-01 2013-05-21 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8071095B2 (en) 2007-11-01 2011-12-06 Perseid Therapeutics, LLC Immunosuppressive polypeptides and nucleic acids
US20110177071A1 (en) * 2007-11-01 2011-07-21 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8318176B2 (en) 2007-11-01 2012-11-27 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8283447B2 (en) 2007-11-01 2012-10-09 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20110129875A1 (en) * 2007-11-01 2011-06-02 Perseid Therapeutics Llc Immunosupprressive polypeptides and nucleic acids
US20110166324A1 (en) * 2007-11-01 2011-07-07 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20110159542A1 (en) * 2007-11-01 2011-06-30 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2623112A1 (de) 2008-06-27 2013-08-07 Zymogenetics, Inc. Lösliche hybride FC-Gamma-Rezeptoren und zugehörige Verfahren
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2011156356A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
US8822642B2 (en) 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
US9441029B2 (en) 2010-08-06 2016-09-13 Genzyme Corporation VEGF antagonist compositions and uses thereof
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
WO2014079384A1 (zh) 2012-11-22 2014-05-30 苏州康宁杰瑞生物科技有限公司 促激素融合蛋白及其制备方法和用途
US9969786B2 (en) 2012-11-22 2018-05-15 Suzhou Alphamab Co, Ltd. Trophic hormone fusion protein, preparation method and application thereof
US10167336B2 (en) 2013-03-14 2019-01-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US11136393B2 (en) 2013-10-01 2021-10-05 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of Bim
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US11504376B2 (en) 2014-07-23 2022-11-22 Mayo Foundation For Medical Education And Research Targeting DNA-PKCS and B7-H1 to treat cancer
US9724390B2 (en) 2015-02-03 2017-08-08 Oncomed Pharmaceuticals, Inc. Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents
US10232017B2 (en) 2015-02-03 2019-03-19 Oncomed Pharmaceuticals, Inc. Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
CN107406878A (zh) * 2015-02-03 2017-11-28 昂科梅德制药有限公司 肿瘤坏死因子受体超家族(tnfrsf)结合剂类及其用途
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
WO2021138264A1 (en) 2019-12-30 2021-07-08 Seagen Inc. Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US11820827B2 (en) 2019-12-30 2023-11-21 Seagen Inc. Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Also Published As

Publication number Publication date
EP1762623A1 (de) 2007-03-14
IE890172L (en) 1989-07-22
DK175949B1 (da) 2005-08-15
ES2092468T3 (es) 1996-12-01
CA1340908C (en) 2000-02-22
JP3424823B2 (ja) 2003-07-07
IE80960B1 (en) 1999-07-14
AU628035B2 (en) 1992-09-10
DE721983T1 (de) 2002-07-04
AU2866889A (en) 1989-07-27
GR3021102T3 (en) 1996-12-31
DE68926888T2 (de) 1997-01-09
DK25489A (da) 1989-07-23
EP0325224A3 (de) 1991-04-17
EP0325224B1 (de) 1996-07-31
DK25489D0 (da) 1989-01-20
EP0325224A2 (de) 1989-07-26
DE68926888D1 (de) 1996-09-05
ATE140963T1 (de) 1996-08-15
JPH0231688A (ja) 1990-02-01
EP0721983A1 (de) 1996-07-17

Similar Documents

Publication Publication Date Title
US5155027A (en) Method of producing secreted receptor analogs and biologically active peptide dimers
US5567584A (en) Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6323323B1 (en) Ligand-binding, dimerized polypeptide fusions
US5889149A (en) Purified PDGF AB isoform and method of making it
US5763224A (en) Decay accelerating factor (DAF) and nucleic acids encoding it
CA1341411C (en) Method for producing fv fragments in eukaryotic cells
JP2594900B2 (ja) マルチチエインポリペプチドまたは蛋白質およびそれらの製造方法
US5888773A (en) Method of producing single-chain Fv molecules
AU616672B2 (en) Growth hormone receptor
JPH09509054A (ja) 抗体部分および非抗体部分を含む融合タンパク質
US5965405A (en) Method for producing Fv fragments in eukaryotic cells
AU629920B2 (en) Type oc platelet-derived growth factor receptor gene
US5688763A (en) Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
JPH05304992A (ja) ハイブリッド・モノクローナル抗体および抗体含有薬剤
US20020055129A1 (en) Antibodies for the alpha platelet-derived growth factor receptor
DK176057B1 (da) Fremgangsmåde til fremstilling af en secerneret, biologisk aktiv peptiddimer
EP0548867A2 (de) Wasserlöslicher Stammzellenfaktor-Rezeptor
US7252929B2 (en) Methods for identifying alpha PDGFR agonists and antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZYMOGENETICS, INC., A CORP. OF WA, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SLEDZIEWSKI, ANDRZEJ Z.;BELL, LILLIAN A.;KINDSVOGEL, WAYNE R.;REEL/FRAME:005129/0084;SIGNING DATES FROM 19890612 TO 19890622

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12